



New connection on: : 24-09-2020 : 23:39:22 - Last disconnection on: : 24-09-2020 : 23:26:06

V 4.0.0.44803(LP,U,linux) (Rev:43856 2017-04-27 09:03:29 +0200#(D201820)) (RPM D201820)

Welcome to EPOQUE Rebuild under the Production Environment

[EPODOC: SS 2] cancer and monitor+ and gleason

Results in EPODOC 4

[SS 3] ..li



1/4 © EPODOC / EPO

PN - [US2005272052](#) A1 20051208

PR - US20030411537 20030409; US20040975592 20041027; US20020371304P 20020409

AP - US20040975592 20041027

DT - *; Rep

CT - || R141 (A1)
[US6335170](#) B1 00000000 [];
[US6335470](#) B1 00000000 [];
[US6262245](#) B1 00000000 [];
[US6268165](#) B1 00000000 [];
[US6413228](#) B1 00000000 [];
[US6413780](#) B1 00000000 [];
[US6423543](#) B1 00000000 [];
[US5981830](#) A 00000000 []

CCI - [C12Q1/6886](#)

CCA - [C12Q2600/112](#) ; [C12Q2600/118](#) ; [C12Q2600/136](#) ; [C12Q2600/158](#)

CI - C12Q1/6886 (EP)

CA - C12Q2600/112 (EP)
- C12Q2600/118 (EP)
- C12Q2600/136 (EP)
- C12Q2600/158 (EP)

PA - AFFYMETRIX INC [US]

TI - Molecular genetic profiling of **gleason** grades 3 and 4/5 prostate **cancer**

AB - Many genes are affected in prostate cancers which have not been previously identified. This includes genes that have been up-regulated or down-regulated. **Monitoring** the expression levels of these genes is useful to identify the existence of prostate **cancer**. Also, **monitoring** the expression levels of these genes is useful to predict the effectiveness of treatment, outcome, use of therapeutics, and screening drugs useful for the treatment of prostate **cancer**.

2/4 © EPODOC / EPO

PN - [US2004029151](#) A1 20040212

PR - US20030411537 20030409; US20020371304P 20020409

AP - US20030411537 20030409

DT - *; Rep

CT - || R141 (A1)
[US6335170](#) B1 00000000 [];
[US2003113762](#) A1 00000000 [];
[US6262245](#) B1 00000000 [];
[US6268165](#) B1 00000000 [];
[US6413228](#) B1 00000000 [];
[US6413780](#) B1 00000000 [];
[US6423543](#) B1 00000000 [];
[US5807522](#) A 00000000 [];
[US5688641](#) A 00000000 [];
[US5981830](#) A 00000000 []

CCI - [C12Q1/6886](#)

CCA - [C12Q2600/112](#) ; [C12Q2600/136](#)

CI - C12Q1/6886 (EP)

CA - C12Q2600/112 (EP)
- C12Q2600/136 (EP)

PA - AFFYMETRIX INC [US]

TI - Molecular genetic profiling of **gleason** grades 3 and 4/5 prostate **cancer**

AB - Many genes are affected in prostate cancers which have not been previously identified. This includes genes that have been up-regulated or down-regulated. **Monitoring** the expression levels of these genes is useful to identify the existence of prostate **cancer**. Also, **monitoring** the expression levels of these genes is useful to predict the effectiveness of treatment, outcome, use of therapeutics, and screening drugs useful for the treatment of prostate **cancer**.

3/4 © EPODOC / EPO

PN - [US2003113762](#) A1 20030619

PR - US20020222206
20020816; US20010312745P
20010817

AP - US20020222206 20020816

DT - **

CT - || R141 (A1)
[US6335170](#) B1 00000000 [];
[US6340565](#) B1 00000000 [];
[US2003013097](#) A1 00000000
[];
[US2004029151](#) A1 00000000
[];
[US6228575](#) B1 00000000 [];
[US6258536](#) B1 00000000 [];
[US6262245](#) B1 00000000 [];
[US6268165](#) B1 00000000 [];
[US6413228](#) B1 00000000 [];
[US6413780](#) B1 00000000 [];
[US6423543](#) B1 00000000 [];
[US5800992](#) A 00000000 [];
[US6303301](#) B1 00000000 [];
[US6309822](#) B1 00000000 [];
[US6309823](#) B1 00000000 [];
[US5981830](#) A 00000000 []

CCI - [C12Q1/6886](#)


CCA - [C12Q2600/158](#)

CI - C12Q1/6886 (EP)

CA - C12Q2600/158 (EP)

TI - **Gleason** grade 4/5
prostate **cancer** genes


AB - Sixty-four down regulated and
22 up regulated genes have
been indentified in **Gleason**
grade 4/5 **cancer**, using the
gene profile from benign
prostatic hyperplasia as
control tissue. Hepsin
appears to be the most
promising of the up regulated
genes. PSMA is also highly
overexpressed at the
transcript level in grade
4/5 **cancer**, re-emphasizing its
potential importance as a
target for chemotherapy. The
regulated genes can be used
diagnostically,
prognostically, and
therapeutically. They can be
used to form prostate specific



expression **monitoring** tools.

4/4 © EPODOC / EPO

- PN - [WO03016484](#) A2 20030227
- PNFP - [WO03016484](#) A3 20031211
- PR - [US20010312745P](#) 20010817
- AP - [WO2002US26081](#) 20020816
- DT - *
- Rep
- CT - |US| ISR (A3)
- [WO9736179](#) A1 00000000 [X];
- [US6268165](#) B1 00000000 [X];
- [XP001098438](#) A[X];
- [US5981830](#) A 00000000 [Y];
- [US6262245](#) B1 00000000 [Y] (XU ET AL);
- [US6413228](#) B1 00000000 [XP];
- [US6423543](#) B1 00000000 [XP];
- [US6413780](#) B1 00000000 [XP];
- [US6335170](#) B1 00000000 [XP]
- CTNP - |US| ISR (A3)
- [X] - MAGEE J.A. ET AL.,
- "Expression profiling hepsin overexpression in prostate cancer", CANCER RESEARCH, (200108), vol. 61, no. 15, pages 5692 - 5696, XP001098438
- CCI - [C12Q1/6886](#)
- CCA - [C12Q2600/158](#)
- CI - [C12Q1/6886](#) (EP)
- CA - [C12Q2600/158](#) (EP)
- PA - (A2 A3)
- AFFYMETRIX INC [US]
- TI - (A2 A3)
- GLEASON** GRADE 4/5
- PROSTATE **CANCER** GENES
- AB - (A2 A3)
- Sixty-four down regulated and 22 up regulated genes have been identified in **Gleason** grade 4/5 **cancer**, using the gene profile from benign prostatic hyperplasia as control tissue. Hepsin appears to be the most promising of the up regulated genes. PSMA is also highly overexpressed at the transcript level in grade 4/5 **cancer**, re-emphasizing its



potential importance as a target for chemotherapy. The regulated genes can be used diagnostically, prognostically, and therapeutically. They can be used to form prostate specific expression **monitoring** tools.

[SS 3] (monitor+ or scal+) and cancer and prostate

Results in EPODOC **726**

[SS 4] 3 and /IC (G01N and A61K)

Results in EPODOC **187**

[SS 5] 4 and biopsy

Results in EPODOC **0**

[SS 6] 4 and sampl+

Results in EPODOC **6**

[SS 7] ..li



1/6 © EPODOC / EPO

- PN - [US2020281946](#) A1 20200910
- PR - US202016867432 20200505; US201815764837 20180329; WO2016US57210 20161014; US201562259426P 20151124; US201562241574P 20151014
- AP - US202016867432 20200505
- DT - **
- CCI - [A61K31/58](#) ; [A61K31/69](#) ; [A61K38/005](#) ; [A61K38/05](#) ; [A61P35/00](#)
- CLC - [A61K31/58](#) , [A61K2300/00](#) , INV
- [A61K31/69](#) , [A61K2300/00](#) , INV
- CI - A61K31/58 (EP, US)
- A61K31/69 (EP, US)
- A61K38/005 (EP, US)
- A61K38/05 (EP, US)
- A61P35/00 (EP, US)
- G01N33/57434 (US)
- CA - G01N2333/47 (US)
- G01N2333/4703 (US)
- G01N2333/723 (US)
- G01N2333/91275 (US)
- G01N2800/52 (US)
- CL - A61K31/58, A61K2300/00, INV (EP, US)

- A61K31/69, A61K2300/00, INV (EP, US)

PA - UNIV WAYNE STATE [US]

TI - TREATMENTS AND DIAGNOSTICS FOR CANCERS

AB - Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin $\alpha 2$ cleavage products or inhibition of DUB activities from a blood **sample** to **monitor** treatment efficacy for castration-resistant **prostate cancer** (CRPC) or multiple myeloma (MM).

2/6 © EPODOC / EPO

PN - [US2018280412](#) A1 20181004

PNFP - US10682362 B2 20200616

PR - US201615764837 20161014; US201562259426P 20151124; US201562241574P 20151014; WO2016US57210 20161014

AP - US201615764837 20161014

DT - **

CT - || STSE (B2)
[US2014107180](#) A1 20140417 [] (MACLEOD ROBERT A [US], et al)

CTNP - || STSE (B2)
[] - Kraft et al. Cancer Biology & Therapy, (2011), 12(2), p. 119-124.
[] - Milacic et al., Int. J. Oncol., (2009), 35(6), p. 1481-1491.

CCI - [A61K31/58](#) ; [A61K31/69](#) ; [A61K38/005](#) ; [A61K38/05](#) ; [A61P35/00](#)

CLC - [A61K31/58](#), [A61K2300/00](#) , INV
- [A61K31/69](#), [A61K2300/00](#) , INV

CI - A61K31/58 (EP, US)
- A61K31/69 (EP, US)
- A61K38/005 (EP, US)
- A61K38/05 (EP, US)
- A61P35/00 (EP, US)
- G01N33/57434 (US)

CA - G01N2333/47 (US)
- G01N2333/4703 (US)
- G01N2333/723 (US)
- G01N2333/91275 (US)
- G01N2800/52 (US)

CL - A61K31/58, A61K2300/00, INV (EP, US)
- A61K31/69, A61K2300/00, INV (EP, US)

PA - (A1)
DOU QINGPING [US]; YANG HUANJIE [CA]; HEATH ELISABETH I [US]
- (B2)
UNIV WAYNE STATE [US]

TI - (A1)
TREATMENTS AND DIAGNOSTICS FOR CANCERS
- (B2)
Treatments and diagnostics for cancers

AB - (A1 B2)
 Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin $\alpha 2$ cleavage products or inhibition of DUB activities from a blood **sample** to **monitor** treatment efficacy for castration-resistant **prostate cancer** (CRPC) or multiple myeloma (MM).

3/6 © EPODOC / EPO

PN - [NZ615915](#) A 20150828

PR - WO2012GB00285 20120328; GB20110005129 20110328

AP - NZ20120615915 20120328

DT - I

CCI - [A61P35/00](#) ; [A61P43/00](#) ; [C07K14/705](#) ; [C12N15/1135](#) ; [C12N15/1138](#) ; [G01N33/57415](#) ; [G01N33/57423](#) ; [G01N33/57434](#)

CCA - [C12N2310/14](#) ; [G01N2800/52](#)

CI - A61P35/00 (EP)
 - A61P43/00 (EP)
 - C07K14/47 (US)
 - C07K14/705 (EP, US)
 - C07K16/18 (US)
 - C12N15/113 (US)
 - C12N15/1135 (EP, US)
 - C12N15/1138 (EP, US)
 - G01N33/57415 (EP, US)
 - G01N33/57423 (EP, US)
 - G01N33/57434 (EP, US)
 - G01N33/57492 (US)

CA - C12N2310/14 (EP, US)
 - G01N2800/52 (EP, US)

PA - HOX THERAPEUTICS LTD

TI - Compositions and methods for treating, diagnosing and **monitoring** disease

AB - Disclosed is the use of a therapeutically effective amount of a composition which inhibits the expression of the TMEM92 gene or which inhibits the function of the TMEM92 protein, in the manufacture of a medicament for the treatment of **cancer**. Also disclosed is a method for diagnosing **cancer** in a patient or for identifying a patient at risk of developing **cancer**, the method comprising: (a) determining an amount of a biomarker in a **sample** obtained from a patient, the biomarker comprising:- (i) a nucleic acid sequence comprising SEQ ID NO:1, or a functional fragment/variant that has at least about 70% nucleic acid sequence identity with SEQ ID NO:1, or a nucleic acid molecule which comprises said nucleic acid sequence; or (ii) an amino acid sequence comprising SEQ ID NO:2, or a functional fragment/variant that has at least about 70% amino acid sequence identity with SEQ ID NO:2, or an amino acid molecule which comprises said amino acid sequence, optionally wherein the biomarker is a **cancer** biomarker selected from a **prostate cancer** biomarker, a non-small cell lung **cancer** biomarker and breast **cancer** biomarker.

- PN - [WO2014205555](#) A1 20141231
- PNFP - WO2014205555 A8 20150129
- PR - US201361841225P 20130628
- AP - WO2014CA00538 20140627
- DT - *; Rep
- CT - |CA| ISR (A1)
[WO2012068383](#) A2 20120524
 [A] (UNIV MICHIGAN [US], et al);
[US2011136683](#) A1 20110609
 [A] (DAVICIONI ELAI [CA]);
[US2013267443](#) A1 20131010
 [AP] (CHINNAIYAN ARUL [US], et al)
- CTNP - |CA| ISR (A1)
 [XP] - CREA, F. ET AL.,
 "Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.",
 ONCOTARGET, (20140206), vol. 5, no. 3, pages 764 - 774
- CCI - [A61K31/7088](#) ; [A61K31/713](#) ;
[A61P35/00](#) ; [C12N15/113](#) ;
[C12Q1/6886](#)
- CCA - [C12N2310/14](#) ; [C12Q2600/158](#)
- CI - A61K31/7088 (EP)
 - A61K31/713 (EP, US)
 - A61P35/00 (EP)
 - C12N15/113 (EP, US)
 - C12Q1/6886 (EP, US)
- CA - C12N2310/14 (EP, US)
 - C12Q2600/158 (EP, US)
- PA - (A1 A8)
 BRITISH COLUMBIA CANCER AGENCY [CA]
- TI - (A1 A8)
 METHODS AND USES FOR DIAGNOSIS AND TREATMENT OF **PROSTATE CANCER**
- AB - (A1 A8)
 In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment **monitoring** of **prostate cancer** (PCa) in a subject. In another aspect,




Figure 3

methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous **prostate** cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (lncRNA), whose expression is significantly altered in biological **samples** obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to **prostate** tissue and is elevated in both cancerous **prostate** tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of **cancer**.

5/6 © EPODOC / EPO

PN - [US2010150930](#) A1 20100617

PR - US20080524388 20080124; US20070897690P 20070126; US20070917382P 20070511; WO2008US51899 20080124

AP - US20080524388 20080124

DT - **

CT - || R141 (A1)
[US5279941](#) A 19940118 [] (LESSEY BRUCE [US])

CTNP - || R141 (A1)
[] - CDC MMWR Surveillance Summary relating to assisted reproduction in the U.S. in 2000 (downloaded on 18 October 2012 from cdc.gov/mmwr/preview/mmwrhtml/ss5209a1.htm; 20 pages total.

CCI - [A61K39/0011](#) ; [C07K14/4748](#) ; [C07K16/30](#) ; [G01N33/57434](#) ; [G01N33/689](#)

CCA - [G01N2800/367](#)

CI - A61K39/0011 (EP, US)
- A61K39/001186 (US)
- C07K14/4748 (EP, US)
- C07K16/30 (EP, US)
- G01N33/57434 (EP, US)
- G01N33/689 (EP, US)

CA - G01N2800/367 (EP, US)

PA - UNIV NORTH CAROLINA [US]

TI - MAGE-11 AS A MARKER FOR ENDOMETRIAL RECEPTIVITY TO EMBRYO TRANSPLANTATION AND A MARKER AND THERAPEUTIC TARGET IN CASTRATION-RECURRENT **PROSTATE CANCER**

AB - Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent **prostate cancer** are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-A1) in an endometrial or **prostate** tissue **sample**. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent **prostate cancer** in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent **prostate cancer**. Methods for **monitoring** endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers.

6/6 © EPODOC / EPO

PN - [JP2009131287](#) A 20090618

PR - US20010016604 20011207; US20010340640P 20011207; WO2001US47824 20011207; US20020388046P 20020612

AP - JP20090065310 20090317

DT - I

CT - || STSE (A)
[WO9725431](#) A1 19970717 [] (CORIXA CORP [US])

CCI - [A61P13/08](#) ; [A61P31/14](#) ; [A61P35/00](#) ; [A61P37/04](#) ; [A61P43/00](#) ; [C07K14/005](#) ; [C07K14/4748](#) ; [C12N7/00](#) ; [C12Q1/6886](#) ; [C12Q1/702](#) ; [G01N33/57434](#)

CCA - [C12N2740/10021](#) ; [C12N2740/10022](#) ; [C12Q2600/136](#) ; [G01N2333/15](#)

CI - A61P13/08 (EP)
- A61P31/14 (EP)
- A61P35/00 (EP)
- A61P37/04 (EP)
- A61P43/00 (EP)
- C07K14/005 (EP)
- C07K14/4748 (EP)
- C12N7/00 (EP)
- C12Q1/6886 (EP)
- C12Q1/702 (EP)
- G01N33/57434 (EP)

CA - C12N2740/10021 (EP)
- C12N2740/10022 (EP)
- C12Q2600/136 (EP)
- G01N2333/15 (EP)

FI - A61K31/713; A61K37/02; A61K38/00; A61K38/02; A61K39/00&H; A61K39/395&U; A61K48/00; A61P35/00; A61P37/04; A61P43/00&107; C07K14/01; C07K16/08; C12N15/00&A; C12Q1/68&A+ZNA; C12Q1/6886&C; C12Q1/6886&Z; G01N33/574&A

FT - 4B024/AA12; 4B024/BA45; 4B024/BA51; 4B024/CA01; 4B024/HA12; 4B063/QA01;

4B063/QA18; 4B063/QA19; 4B063/QQ02; 4B063/QQ43; 4B063/QQ46; 4B063/QQ53;
 4B063/QQ58; 4B063/QR08; 4B063/QR32; 4B063/QR42; 4B063/QR55; 4B063/QR62;
 4B063/QS25; 4B063/QS34; 4B063/QX02; 4C084/AA02; 4C084/AA13; 4C084/BA03;
 4C084/CA70; 4C084/NA14; 4C084/ZB09; 4C084/ZB22; 4C084/ZB26; 4C085/AA03;
 4C085/AA14; 4C085/CC08; 4C085/EE01; 4C085/EE06; 4C085/FF21; 4C085/FF24;
 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/EA16; 4C086/MA01; 4C086/MA04;
 4C086/NA14; 4C086/ZB09; 4C086/ZB22; 4C086/ZB26; 4H045/AA10; 4H045/AA11;
 4H045/BA10; 4H045/CA01; 4H045/CA40; 4H045/DA76; 4H045/DA86; 4H045/EA28;
 4H045/FA74

- PA - NOVARTIS VACCINES & DIAGNOSTIC
- TI - ENDOGENOUS RETROVIRUS UP-REGULATED IN **PROSTATE CANCER**
- AB - PROBLEM TO BE SOLVED: To provide improved materials and methods that can be used in the diagnosis, prevention and treatment of **prostate cancer**.
 - SOLUTION: A method for diagnosing **cancer**, especially **prostate cancer**, the method comprises the step of detecting in a patient **sample** the presence or absence of an expression product of a human endogenous retrovirus (PCAV) located at megabase 20.428 on chromosome 22. A method of screening for compounds with activity against **cancer**, comprises: contacting a test compound with a tissue **sample** derived from a cell in which expression of the human endogenous retrovirus located at megabase 20.428 on chromosome 22 is up-regulated; and **monitoring** expression of the retrovirus in the **sample**, wherein a decrease in expression indicates anti-**cancer** efficacy of the test compound.
 - COPYRIGHT: (C)2009,JPO&INPIT

[SS 7] ..li ss 4 1-50



1/187 © EPODOC / EPO

- PN - [US2020281946](#) A1 20200910
- PR - US202016867432 20200505; US201815764837 20180329; WO2016US57210 20161014; US201562259426P 20151124; US201562241574P 20151014
- AP - US202016867432 20200505
- DT - **
- CCI - [A61K31/58](#) ; [A61K31/69](#) ; [A61K38/005](#) ; [A61K38/05](#) ; [A61P35/00](#)
- CLC - [A61K31/58](#) , [A61K2300/00](#) , INV
 - [A61K31/69](#) , [A61K2300/00](#) , INV
- CI - A61K31/58 (EP, US)
 - A61K31/69 (EP, US)
 - A61K38/005 (EP, US)
 - A61K38/05 (EP, US)
 - A61P35/00 (EP, US)
 - G01N33/57434 (US)
- CA - G01N2333/47 (US)
 - G01N2333/4703 (US)
 - G01N2333/723 (US)
 - G01N2333/91275 (US)
 - G01N2800/52 (US)
- CL - A61K31/58, A61K2300/00, INV (EP, US)
 - A61K31/69, A61K2300/00, INV (EP, US)

PA - UNIV WAYNE STATE [US]
 TI - TREATMENTS AND DIAGNOSTICS FOR CANCERS
 AB - Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin $\alpha 2$ cleavage products or inhibition of DUB activities from a blood sample to **monitor** treatment efficacy for castration-resistant **prostate cancer** (CRPC) or multiple myeloma (MM).

2/187 © EPODOC / EPO

PN - [JP2019205431](#) A 20191205
 PR - EP20090159960 20090512; EP20090169739 20090908
 AP - JP20190104594 20190604
 DT - I
 CCI - [A61P13/08](#) ; [A61P35/00](#) ; [A61P43/00](#) ; [C12N9/16](#) ; [C12N15/1137](#) ; [C12N15/115](#) ; [C12Q1/44](#) ; [C12Q1/6886](#) ; [C12Y301/04017](#) ; [G01N33/57434](#)
 CCA - [C12N2310/11](#) ; [C12N2310/14](#) ; [C12N2310/16](#) ; [C12Q2600/106](#) ; [C12Q2600/112](#) ; [C12Q2600/158](#) ; [G01N2800/52](#)
 CI - A61P13/08 (EP)
 - A61P35/00 (EP)
 - A61P43/00 (EP)
 - C12N9/16 (EP, KR)
 - C12N15/1137 (EP, KR)
 - C12N15/115 (EP, KR)
 - C12Q1/44 (EP)
 - C12Q1/6886 (EP, KR)
 - C12Y301/04017 (EP)
 - G01N33/57434 (EP, KR)
 - G01N33/6893 (KR)
 CA - C12N2310/11 (EP)
 - C12N2310/14 (EP)
 - C12N2310/16 (EP)
 - C12Q2600/106 (EP, KR)
 - C12Q2600/112 (EP)
 - C12Q2600/118 (KR)
 - C12Q2600/158 (EP, KR)
 - G01N2800/342 (KR)
 - G01N2800/52 (EP, KR)
 FI - A61K31/7088; A61K31/7105; A61K39/395&D; A61K39/395&N; A61K45/00; A61K48/00; A61P13/08; A61P35/00; A61P43/00&111; C12N15/115&Z; C12N9/16&C; C12Q1/44+ZNA; G01N33/574&A; G01N33/68
 FT - 2G045/AA26; 2G045/CA25; 2G045/CB01; 2G045/CB02; 2G045/CB03; 2G045/CB07; 2G045/CB14; 2G045/DA20; 2G045/DA36; 2G045/FB03; 4B050/CC10; 4B050/DD11; 4B050/KK13; 4B050/LL03; 4B063/QA01; 4B063/QA19; 4B063/QQ02; 4B063/QQ08; 4B063/QQ33; 4B063/QR16; 4B063/QR32; 4B063/QR35; 4B063/QR55; 4B063/QS32; 4B063/QS33; 4B063/QX02; 4C084/AA13; 4C084/AA17; 4C084/NA05; 4C084/NA14; 4C084/ZA811; 4C084/ZA812; 4C084/ZB261; 4C084/ZB262; 4C084/ZC201;

4C084/ZC202; 4C085/AA13; 4C085/AA14; 4C085/BB01; 4C085/EE01; 4C086/AA01;
4C086/AA02; 4C086/EA16; 4C086/MA01; 4C086/MA04; 4C086/NA05; 4C086/NA14;
4C086/ZA81; 4C086/ZB26; 4C086/ZC20

- PA - KONINKLIJKE PHILIPS NV; UNIV COURT OF THE UNIV OF GLASGOW
- TI - PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT HORMONE-SENSITIVE **PROSTATE CANCER**
- AB - To provide a novel and effective alternative diagnostic aspect for detection, **monitoring** and prognosis of **prostate cancer**, especially malignant hormone-sensitive **prostate cancer**. SOLUTION: There is provided a use of phosphodiesterase 4D7 (PDE4D7) as a marker for malignant hormone-sensitive **prostate cancer**, which is expressed at a higher level in malignant hormone-sensitive **prostate cancer** tissue when compared with the expression in a normal tissue or a benign **prostate** tumor tissue. There is provided a compositions for diagnosing, detecting, **monitoring** or prevising malignant hormone-sensitive **prostate cancer**, a corresponding detection method, a method for differentiation of benign and malignant hormone-sensitive **prostate** cancers, data collection method and a corresponding immunological assay. There is provided a method for specifying individuals for eligibility for malignant hormone-sensitive **prostate cancer** and an immunological assay that stratifies individuals suffering from such **prostate cancer**. There is provided a pharmaceutical composition and a use thereof for the treatment of malignant hormone sensitive **prostate cancer**. SELECTED DRAWING: Figure 4

3/187 © EPODOC / EPO

- PN - [US2019255045](#) A1 20190822
- PR - US201916398802 20190430; US201815966844 20180430; US201715420283 20170131; US201514947345 20151120; US201414173588 20140205; US201361831823P 20130606; US201361813122P 20130417
- AP - US201916398802 20190430
- DT - **
- CCI - [A61K31/496](#) ; [A61K31/519](#) ; [A61K31/58](#) ; [A61K33/24](#) ; [A61K45/06](#) ; [A61P3/00](#) ; [A61P13/08](#) ; [A61P31/00](#) ; [A61P31/10](#) ; [A61P35/00](#)
- CLC - [A61K31/496](#) , [A61K2300/00](#) , INV
- [A61K31/519](#) , [A61K2300/00](#) , INV
- [A61K31/58](#) , [A61K2300/00](#) , INV
- [A61K33/24](#) , [A61K2300/00](#) , INV
- CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)
- A61K31/58 (EP, KR, MX, US)
- A61K33/24 (EP, KR, MX, US)
- A61K45/06 (EP, KR, MX, US)
- A61P3/00 (EP)
- A61P13/08 (EP)
- A61P31/00 (EP)
- A61P31/10 (EP)
- A61P35/00 (EP, KR)
- G01N33/57484 (KR, MX, US)

- CA - A61K2300/00 (KR)
- G01N2333/96455 (KR, MX, US)
- CL - A61K31/496, A61K2300/00, INV (EP, US)
- A61K31/519, A61K2300/00, INV (EP, US)
- A61K31/519, A61K2300/00, A61K31/496, A61K2300/00%2, A61K33/24, A61K2300/00%3, A61K31/58, A61K2300/00%4, INV (MX)
- A61K31/58, A61K2300/00, INV (EP, US)
- A61K33/24, A61K2300/00, INV (EP, US)
- PA - HEDGE PATH PHARMACEUTICALS INC [US]
- TI - TREATMENT AND PROGNOSTIC **MONITORING** OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
- AB - The present invention concerns methods for treating a proliferation disorder, such as **prostate cancer**, basal cell carcinoma, lung **cancer**, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for **monitoring** subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

4/187 © EPODOC / EPO

- PN - [US2019255044](#) A1 20190822
- PR - US201916398756 20190430; US201815966844 20180430; US201715420283 20170131; US201514947345 20151120; US201414173588 20140205; US201361831823P 20130606; US201361813122P 20130417
- AP - US201916398756 20190430
- DT - **
- CCI - [A61K31/496](#) ; [A61K31/519](#) ; [A61K31/58](#) ; [A61K33/24](#) ; [A61K45/06](#) ; [A61P3/00](#) ; [A61P13/08](#) ; [A61P31/00](#) ; [A61P31/10](#) ; [A61P35/00](#)
- CLC - [A61K31/496](#) , [A61K2300/00](#) , INV
- [A61K31/519](#) , [A61K2300/00](#) , INV
- [A61K31/58](#) , [A61K2300/00](#) , INV
- [A61K33/24](#) , [A61K2300/00](#) , INV
- CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)
- A61K31/58 (EP, KR, MX, US)
- A61K33/24 (EP, KR, MX, US)
- A61K45/06 (EP, KR, MX, US)
- A61P3/00 (EP)
- A61P13/08 (EP)
- A61P31/00 (EP)
- A61P31/10 (EP)
- A61P35/00 (EP, KR)
- G01N33/57484 (KR, MX, US)
- CA - A61K2300/00 (KR)
- G01N2333/96455 (KR, MX, US)
- CL - A61K31/496, A61K2300/00, INV (EP, US)
- A61K31/519, A61K2300/00, INV (EP, US)


- A61K31/519, A61K2300/00, A61K31/496, A61K2300/00%2, A61K33/24, A61K2300/00%3, A61K31/58, A61K2300/00%4, INV (MX)
- A61K31/58, A61K2300/00, INV (EP, US)
- A61K33/24, A61K2300/00, INV (EP, US)
- PA - HEDGE PATH PHARMACEUTICALS INC [US]
- TI - TREATMENT AND PROGNOSTIC **MONITORING** OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
- AB - The present invention concerns methods for treating a proliferation disorder, such as **prostate cancer**, basal cell carcinoma, lung **cancer**, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for **monitoring** subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

5/187 © EPODOC / EPO

- PN - [CA3042506](#) A1 20180511
- PR - US201662415893P 20161101; WO2017US59573 20171101
- AP - CA20173042506 20171101
- DT - I
- CCI - [C07K16/18](#) ; [G01N33/57434](#)
- CCA - [C07K2317/92](#) ; [G01N2333/4742](#)
- CI - A01K67/0275 (US)
- C07K16/18 (EP, US)
- C07K16/3069 (US)
- G01N33/57434 (EP, US)
- CA - A01K2217/05 (US)
- A01K2227/105 (US)
- C07K2317/21 (US)
- C07K2317/56 (US)
- C07K2317/565 (US)
- C07K2317/92 (EP, US)
- G01N2333/47 (US)
- G01N2333/4742 (EP, US)
- G01N2333/96455 (US)
- PA - BERG LLC [US]; TANNA NIKUNJ NARENDRA [US]
- TI - FILAMIN A BINDING PROTEINS AND USES THEREOF
- AB - The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, **monitoring** and prognosis or **prostate cancer** are also provided.

6/187 © EPODOC / EPO

- PN - [JP2019059733](#) A 20190418
- PR - EP20090159960 20090512
- AP - JP20180205900 20181031
- DT - I
- CCI - [A61P13/08](#) ; [A61P35/00](#) ;



	A61P43/00 ; C12N9/16 ; C12N15/1137 ; C12N15/115 ; C12Q1/44 ; C12Q1/6886 ; C12Y301/04017 ; G01N33/57434
CCA	- C12N2310/113 ; C12N2310/14 ; C12N2310/141 ; C12N2310/16 ; C12Q2600/106 ; C12Q2600/112 ; G01N2800/52 ; Y10S436/813
CI	- A61P13/08 (EP) - A61P35/00 (EP) - A61P43/00 (EP) - C12N9/16 (EP, CN, KR) - C12N15/1137 (EP, CN, KR) - C12N15/115 (EP, CN, KR) - C12Q1/44 (EP, CN) - C12Q1/6886 (EP, CN, KR, RU) - C12Y301/04017 (EP, CN) - G01N33/57434 (EP, CN, KR) - G01N33/68 (US) - G01N33/6893 (KR)
CA	- C12N2310/113 (EP, CN) - C12N2310/14 (EP, CN) - C12N2310/141 (EP, CN) - C12N2310/16 (EP, CN) - C12Q2600/106 (EP, CN, KR) - C12Q2600/112 (EP, CN, KR) - C12Q2600/118 (KR) - G01N2333/916 (CN, US) - G01N2800/52 (EP, KR) - G01N2800/54 (KR, US) - Y10S436/813 (EP, US)
FI	- A61K49/00+ZNA; A61K49/14; A61P13/08; A61P35/00; C07K16/40; C12N15/115&Z; C12N9/16&C; C12Q1/6851&Z; C12Q1/686&Z; C12Q1/6883&Z; G01N33/573&A
FT	- 4B050/CC03; 4B050/DD11; 4B050/LL01; 4B050/LL03; 4B063/QA13; 4B063/QA19; 4B063/QQ02; 4B063/QQ08; 4B063/QQ42; 4B063/QQ52; 4B063/QQ79; 4B063/QR32; 4B063/QR35; 4B063/QR48; 4B063/QR55; 4B063/QR62;

4B063/QS25; 4B063/QS34;
 4B063/QX02; 4C085/HH01;
 4C085/HH07; 4C085/HH11;
 4C085/HH13; 4C085/JJ02;
 4C085/JJ05; 4C085/JJ17;
 4C085/KA03; 4C085/KA04;
 4C085/KA27; 4C085/KA29;
 4C085/KB82; 4C085/KB92;
 4C085/LL12; 4H045/AA11;
 4H045/AA30; 4H045/BA10;
 4H045/CA40; 4H045/DA75;
 4H045/EA20; 4H045/EA50

PA - KONINKLIJKE PHILIPS NV; UNIV
 COURT OF THE UNIV OF
 GLASGOW


TI - PHOSPHODIESTERASE 4D7
 AS **PROSTATE CANCER** MARKER

AB - To provide a new and
 effective method for
 detection,
 diagnosis, **monitoring** and
 prognostication of **prostate
 cancer**. SOLUTION: The present
 invention relates to the use of
 a pharmaceutical
 composition for diagnosing,
 detecting, **monitoring** or
 prognosticating **cancer** or
 progression of **prostate
 cancer**, the pharmaceutical
 composition comprising a
 nucleic acid affinity ligand
 and/or a peptide affinity
 ligand for a
 phosphodiesterase 4D7
 (PDE4D7) expression product
 or PDE4D7 protein. The
 present invention also relates
 to a method and a
 corresponding immunoassay
 for diagnosing, **monitoring** or
 prognosticating hormone-
 resistant **prostate cancer** vs.
 hormone-sensitive **prostate
 cancer**. SELECTED DRAWING:
 Figure 11

7/187 © EPODOC / EPO

PN - [US2018327863](#) A1 20181115

PR - US201815987235
 20180523; US201313819933
 20130419; WO2011US50487



20110906; US20100379875P
20100903

AP - US201815987235 20180523

DT - **

CCI - [A61K31/7088](#) ; [A61K31/711](#) ;
[C12Q1/6886](#) ; [G01N33/5011](#)

CCA - [C12Q2600/156](#)

CI - A61K31/7088 (EP, US)
- A61K31/711 (EP, US)
- C12Q1/6886 (EP, US)
- G01N33/5011 (EP, US)

CA - C12Q2600/156 (EP, US)

PA - UNIV JOHNS HOPKINS [US]

TI - ARID1A AND PPP2R1A
MUTATIONS IN **CANCER**

AB - Two genes, ARID1A (AT-rich
interactive domain-
containing protein 1A) and
PPP2R1A (protein-
phosphatase 2, regulatory
subunit 1, alpha), can be used
in methods which are useful
for detecting **cancer**,
diagnosing **cancer**,
contributing to a diagnosis
of **cancer**, confirming a
diagnosis of **cancer**,
identifying appropriate
treatments for **cancer**,
monitoring treatment
of **cancer**, and evaluating
treatment protocols
for **cancer**, including ovarian
clear cell carcinoma,
breast **cancer**, colon **cancer**,
gastric **cancer**, lung **cancer**,
medulloblastoma,
pancreatic **cancer**,
and **prostate cancer**.

8/187 © EPODOC / EPO


PN - [US2018280412](#) A1 20181004

PNFP - US10682362 B2 20200616

PR - US201615764837
20161014; US201562259426P

20151124; US201562241574P
20151014; WO2016US57210
20161014

AP - US201615764837 20161014



DT	- **
CT	- STSE (B2) US2014107180 A1 20140417 [] (MACLEOD ROBERT A [US], et al)
CTNP	- STSE (B2) [] - Kraft et al. Cancer Biology & Therapy, (2011), 12 (2), p. 119-124. [] - Milacic et al., Int. J. Oncol., (2009), 35(6), p. 1481- 1491.
CCI	- A61K31/58 ; A61K31/69 ; A61K38/005 ; A61K38/05 ; A61P35/00
CLC	- A61K31/58 , A61K2300/00 , INV - A61K31/69 , A61K2300/00 , INV
CI	- A61K31/58 (EP, US) - A61K31/69 (EP, US) - A61K38/005 (EP, US) - A61K38/05 (EP, US) - A61P35/00 (EP, US) - G01N33/57434 (US)
CA	- G01N2333/47 (US) - G01N2333/4703 (US) - G01N2333/723 (US) - G01N2333/91275 (US) - G01N2800/52 (US)
CL	- A61K31/58, A61K2300/00, INV (EP, US) - A61K31/69, A61K2300/00, INV (EP, US)
PA	- (A1) DOU QINGPING [US]; YANG HUANJIE [CA]; HEATH ELISABETH I [US] - (B2) UNIV WAYNE STATE [US]
TI	- (A1) TREATMENTS AND DIAGNOSTICS FOR CANCERS - (B2) Treatments and diagnostics for cancers
AB	- (A1 B2) Treatments and diagnostics for treatment efficacy against

solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin $\alpha 2$ cleavage products or inhibition of DUB activities from a blood sample to **monitor** treatment efficacy for castration-resistant **prostate cancer** (CRPC) or multiple myeloma (MM).

9/187 © EPODOC / EPO

PN - [US2018243295](#) A1 20180830

PNFP - US10328072 B2 20190625

PR - US201815966613
20180430; US201715420247
20170131; US201514947305
20151120; US201414173588
20140205; US201361831823P

20130606; US201361813122P
20130417

AP - US201815966613 20180430

DT - **

CCI - [A61K31/496](#) ; [A61K31/519](#) ;
[A61K31/58](#) ; [A61K33/24](#) ;
[A61K45/06](#) ; [A61P3/00](#) ;
[A61P13/08](#) ; [A61P31/00](#) ;
[A61P31/10](#) ; [A61P35/00](#)

CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV

- [A61K31/519](#) , [A61K2300/00](#) ,
INV

- [A61K31/58](#) , [A61K2300/00](#) ,
INV

- [A61K33/24](#) , [A61K2300/00](#) ,
INV

CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)

	- A61K31/58 (EP, KR, MX, US) - A61K33/24 (EP, KR, MX, US) - A61K45/06 (EP, KR, MX, US) - A61P3/00 (EP) - A61P13/08 (EP) - A61P31/00 (EP) - A61P31/10 (EP) - A61P35/00 (EP, KR) - G01N33/57484 (KR, MX, US)
CA	- A61K2300/00 (KR) - G01N2333/96455 (KR, MX, US)
CL	- A61K31/496, A61K2300/00, INV (EP, US) - A61K31/519, A61K2300/00, INV (EP, US) - A61K31/519, A61K2300/00, A61K31/496, A61K2300/00% 2, A61K33/24, A61K2300/00% 3, A61K31/58, A61K2300/00% 4, INV (MX) - A61K31/58, A61K2300/00, INV (EP, US) - A61K33/24, A61K2300/00, INV (EP, US)
PA	- (A1 B2) HEDGEPATH PHARMACEUTICALS INC [US]
TI	- (A1) TREATMENT AND PROGNOSTIC MONITORING OF CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS - (B2) Treatment of lung cancer using hedgehog pathway inhibitors
AB	- (A1 B2) The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and

other criteria predictive of
efficacy.

10/187 © EPODOC / EPO

PN - [US2018243296](#) A1 20180830

PNFP - US10363252 B2 20190730

PR - US201815966844
20180430; US201715420283
20170131; US201514947345
20151120; US201414173588
20140205; US201361831823P

20130606; US201361813122P
20130417

AP - US201815966844 20180430

DT - **


CCI - [A61K31/496](#) ; [A61K31/519](#) ;
[A61K31/58](#) ; [A61K33/24](#) ;
[A61K45/06](#) ; [A61P3/00](#) ;
[A61P13/08](#) ; [A61P31/00](#) ;
[A61P31/10](#) ; [A61P35/00](#)

CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K31/519](#) , [A61K2300/00](#) ,
INV
- [A61K31/58](#) , [A61K2300/00](#) ,
INV
- [A61K33/24](#) , [A61K2300/00](#) ,
INV

CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)
- A61K31/58 (EP, KR, MX, US)
- A61K33/24 (EP, KR, MX, US)
- A61K45/06 (EP, KR, MX, US)
- A61P3/00 (EP)
- A61P13/08 (EP)
- A61P31/00 (EP)
- A61P31/10 (EP)
- A61P35/00 (EP, KR)
- G01N33/57484 (KR, MX, US)

CA - A61K2300/00 (KR)
- G01N2333/96455 (KR, MX, US)

CL - A61K31/496, A61K2300/00,
INV (EP, US)
- A61K31/519, A61K2300/00,
INV (EP, US)
- A61K31/519, A61K2300/00,



A61K31/496, A61K2300/00%
 2, A61K33/24, A61K2300/00%
 3, A61K31/58, A61K2300/00%
 4, INV (MX)

- A61K31/58, A61K2300/00,
 INV (EP, US)

- A61K33/24, A61K2300/00,
 INV (EP, US)

PA - (A1 B2)
 HEDGEPATH
 PHARMACEUTICALS INC [US]

TI - (A1)
 TREATMENT AND
 PROGNOSTIC **MONITORING**
 OF NON-CANCEROUS
 PROLIFERATION DISORDERS
 USING HEDGEHOG PATHWAY
 INHIBITORS

- (B2)
 Treatment of **prostate cancer**
 using hedgehog pathway
 inhibitors

AB - (A1 B2)
 The present invention
 concerns methods for treating
 a proliferation disorder, such
 as **prostate cancer**, basal cell
 carcinoma, lung **cancer**, and
 other cancers, using an
 inhibitor of the Hedgehog
 pathway (HhP); and methods
 for **monitoring** subjects
 undergoing such treatments
 based on biomarkers and
 other criteria predictive of
 efficacy.

11/187 © EPODOC / EPO

PN - [US2018171002](#) A1 20180621


PNFP - US10759850 B2 20200901

PR - US201715801093
 20171101; US201662415893P
 20161101

AP - US201715801093 20171101

DT - **

CTNP - || STSE (B2)
 [] - Paul, Fundamental
 Immunology, 3rd Edition,
 1993, pp. 292-295.
 [] - Rudikoff et al., Proc.
 Natl. Acad. Sci. USA, 1982, 79



(6):1979-1983.
 [] - Colman, Research in Immunology, 1994, 145:33-36.
 [] - Bendig, Methods: A Companion to Methods in Enzymology, 1995; 8:83-93.
 [] - Khantasup et al., Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2015, 34(6): 404-417.

CCI - [C07K16/18](#) ; [G01N33/57434](#)

CCA - [C07K2317/92](#) ;
[G01N2333/4742](#)

CI - A01K67/0275 (US)
 - C07K16/18 (EP, US)
 - C07K16/3069 (US)
 - G01N33/57434 (EP, US)

CA - A01K2217/05 (US)
 - A01K2227/105 (US)
 - C07K2317/21 (US)
 - C07K2317/56 (US)
 - C07K2317/565 (US)
 - C07K2317/92 (EP, US)
 - G01N2333/47 (US)
 - G01N2333/4742 (EP, US)
 - G01N2333/96455 (US)

PA - (A1 B2)
 BERG LLC [US]

TI - (A1)
 FILAMIN A BINDING PROTEINS
 AND USES THEREOF
 - (B2)
 Filamin A binding proteins
 and uses thereof

AB - (A1)
 The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, **monitoring** and prognosis or **prostate cancer**

are also provided.

- (B2)

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, **monitoring** and prognosis of **prostate cancer** are also provided.

12/187 © EPODOC / EPO

PN - [WO2018085431](#) A1 20180511

Figure 1

PNFP - WO2018085431 A8 20180607

PR - US201662415893P 20161101

AP - WO2017US59573 20171101

DT - *; Rep

CT - |US| ISR (A1)

[US2016258958](#) A1 20160908
[A] (NARAIN NIVEN RAJIN [US],
et al)

[A] 1-2, 3/1-2, 7, 41-43, 45,
46/41, 46/45, 59-61, 63,
64/59, 64/63, 69-71, 73,
74/69, 74/73, 84-85, 88-89,
90/84, 90/89

* ; abstract; paragraphs
[0015], [0020], [0024], [0031],
[0046], [0061], [0398], [0407]
-[0408], [0414] *;

[XP055083300](#) A[A];

[US2012294861](#) A1 20121122
[A] (SONODA JUNICHIRO [US],
et al)

[A] 1-2, 3/1-2, 7

* ; paragraph [0008]; claim
12 *;

[XP004235726](#) A[A];

[US2014178391](#) A1 20140626
[A] (DOMON BRUNO [CH], et
al)

[A] 41-43, 45, 46/41, 46/45,
59-61, 63, 64/59, 64/63, 59-
71, 73, 74/69, 74/73, 84-86,
88-89, 90/84, 90/89

* ; paragraph [0009]1 *;
[XP055489786](#) A[PX]

CTNP - |US| ISR (A1)
 [A] - BEDOLLA, RG et al.,
 "Nuclear vs Cytoplasmic
 localization of Filamin A in
 Prostate Cancer:
 Immunohistochemical
 Correlation with Metastases",
 Clinical Cancer Research,
 (20090201), vol. 15, no. 3,
 pages 1 - 15, XP055083300
 [A] 1-2, 3/1-2, 7
 * ; page 3, paragraph 3; DOI:
 10.1158/1078-0432.CCR-08-
 1402. *

[A] - FLIER, AVD et al.,
 "Structural and Functional
 Aspects of Filamins",
 Biochimica et Biophysica
 Acta, (20010423), vol. 1538,
 no. 2-3, pages 99 - 117,
 XP004235726
 [A] 41-43, 45, 46/41, 46/45,
 59-61, 63, 64/59, 64/63, 69-
 71, 73, 74/69, 74/73, 84-86,
 88-89, 90/84, 90/89
 * ; page 102, column 1,
 paragraph 2; Genbank
 Supplement pages 1-11 *
 [PX] - RAVIPATY, S et al.,
 "Clinical Validation of a
 Serum Protein Panel (FLNA,
 FLNB and KRT19) for
 Diagnosis of Prostate
 Cancer", Journal of Molecular
 Biomarkers and Diagnosis,
 (20170000), vol. 8, no. 323,
 pages 1 - 8, XP055489786
 [PX] 41-43, 45, 46/41, 46/45,
 59-61, 63, 64/59, 64/63, 69-
 71, 73, 74/69, 74/73, 84-86,
 88-89, 90/84, 90/89
 * ; whole document;
 DOI: [10.4172/2155-
 9929.1000323](#) *

CCI - [C07K16/18](#) ; [G01N33/57434](#)

CCA - [C07K2317/92](#) ;
[G01N2333/4742](#)

CI - A01K67/0275 (US)
 - C07K16/18 (EP, US)
 - C07K16/3069 (US)

CA	- G01N33/57434 (EP, US)
	- A01K2217/05 (US)
	- A01K2227/105 (US)
	- C07K2317/21 (US)
	- C07K2317/56 (US)
	- C07K2317/565 (US)
	- C07K2317/92 (EP, US)
	- G01N2333/47 (US)
	- G01N2333/4742 (EP, US)
	- G01N2333/96455 (US)
PA	- (A1 A8) BERG LLC [US]; TANNA NIKUNJ NARENDRA [US]
TI	- (A1 A8) FILAMIN A BINDING PROTEINS AND USES THEREOF
AB	- (A1) The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.
	- (A8) The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.

PN - [WO2018085441](#) A1 20180511
 PR - US201662415865P 20161101
 AP - WO2017US59586 20171101
 DT - *; Rep
 CT - |US| ISR (A1)
 [US2016258958](#) A1 20160908
 [A] (NARAIN NIVEN RAJIN [US], et al)
 [A] 1-3, 7
 * ; paragraphs [0256], [0414] *;
 [US2015259437](#) A1 20150917
 [A] (VAN VLASSELAER PETER [US], et al)
 [A] 1-3, 7
 * ; paragraph [0226] *;
 [US2013195878](#) A1 20130801
 [A] (MACDONALD LYNN [US], et al)
 [A] 1-3, 7
 * ; paragraph [0012] *;
 [US2008025977](#) A1 20080131
 [A] (YOUNG DAVID S F [CA], et al)
 [A] 7
 * ; paragraphs [0056]. [0092];
 Figure 18; Claim 51 *
 CCI - [C07K16/18](#) ; [G01N33/57434](#)
 CCA - [C07K2317/92](#)
 CI - C07K14/47 (EP)
 - C07K16/18 (EP, US)
 - G01N33/57434 (EP, US)
 CA - C07K2317/565 (US)
 - C07K2317/92 (EP, US)
 PA - BERG LLC [US]
 TI - FILAMIN B BINDING PROTEINS
 AND USES THEREOF
 AB - The present invention encompasses filamin B (FLNB) binding proteins. Specifically, the invention relates to antibodies to FLNB. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, **monitoring** and prognosis or **prostate cancer** are also provided.

Figure 1

14/187 © EPODOC / EPO

PN - [US2018066323](#) A1 20180308

PR - US201715806951
20171108; US201514652611
20150616; WO2014US11211
20140113; US201361752135P
20130113; US201361814480P
20130422; US201361878648P
20130917

AP - US201715806951 20171108

DT - **

CCI - [A61K31/167](#) ; [A61K31/337](#) ;
[A61K31/566](#) ; [A61K38/08](#) ;
[G01N33/57434](#)

CCA - [G01N2800/52](#) ; [G01N2800/56](#)


CI - A61K31/167 (EP, US)
- A61K31/337 (EP, US)
- A61K31/566 (EP, US)
- A61K38/08 (EP)
- C12Q1/6886 (US)
- G01N33/57434 (EP, US)

CA - C12Q2600/112 (US)
- C12Q2600/156 (US)
- C12Q2600/158 (US)
- G01N2333/4703 (US)
- G01N2333/4712 (US)
- G01N2333/475 (US)
- G01N2333/705 (US)
- G01N2800/52 (EP, US)
- G01N2800/56 (EP, US)

PA - UNIV EMORY [US]

TI - Biomarkers in **Cancer**, Methods,
and Systems Related Thereto

AB - This disclosure relates
biomarkers of **cancer**, e.
g. **prostate cancer**. The
biomarkers may be altered
expression of nucleic acids,
mutations, or proteins encoded
therefrom. In certain
embodiments, the disclosure
relates to methods for
diagnosing **prostate cancer**,
methods of distinguishing
between less aggressive and high
aggressive **prostate cancer**,
methods of determining
predisposition to recurrence



of **prostate cancer**, methods
of **monitoring**
progression/regression
of **prostate cancer**, methods of
assessing efficacy of
compositions for
treating **prostate cancer**, and
methods of screening
compositions for activity in
modulating biomarkers
of **prostate cancer**.

15/187 © EPODOC / EPO

PN - [JP2017212973](#) A 20171207

PNFP - JP6588496B B2 20191009

PR - EP20090159960
20090512; EP20090169739
20090908

AP - JP20170092325 20170508

DT - I

CT - || STSE (A)
[WO03044170](#) A2 20030530
[XY] (MEMORY PHARM CORP
[US], et al)
[XY] 1-12
* 請求項20-22, Page37 Line19
- Page38, Pages41-43, Page32
Lines11-14, Page33 Lines5-7,
Page35 Lines15-24, Page42
Lines19-22, Page46 Lines11-
19, Page43 Line16 *;
[JP6246167B](#) B2 20171213 [EX]
[EX] 16
* 請求項1 *

CTNP - || STSE (A)
[Y] - E.P.Rahrmann, et al,
Cancer Researcch,
(20090428), vol. 69, no. 10,
ISSN 0003806681, pages
4388 - 4397
[Y] 1-12
* Abstract, Figures1-6 *

CCI - [A61P13/08](#) ; [A61P35/00](#) ;
[A61P43/00](#) ; [C12N9/16](#) ;
[C12N15/1137](#) ; [C12N15/115](#) ;
[C12Q1/44](#) ; [C12Q1/6886](#) ;
[C12Y301/04017](#) ;
[G01N33/57434](#)

CCA - [C12N2310/11](#) ;
[C12N2310/14](#) ;
[C12N2310/16](#) ;



	<u>C12Q2600/106</u> ; <u>C12Q2600/112</u> ; <u>C12Q2600/158</u> ; <u>G01N2800/52</u>
CI	- A61P13/08 (EP) - A61P35/00 (EP) - A61P43/00 (EP) - C12N9/16 (EP, KR) - C12N15/1137 (EP, KR) - C12N15/115 (EP, KR) - C12Q1/44 (EP) - C12Q1/6886 (EP, KR) - C12Y301/04017 (EP) - G01N33/57434 (EP, KR) - G01N33/6893 (KR)
CA	- C12N2310/11 (EP) - C12N2310/14 (EP) - C12N2310/16 (EP) - C12Q2600/106 (EP, KR) - C12Q2600/112 (EP) - C12Q2600/118 (KR) - C12Q2600/158 (EP, KR) - G01N2800/342 (KR) - G01N2800/52 (EP, KR)
FI	- A61K31/4015; A61K31/7088; - A61K39/395&D; - A61K39/395&E; - A61K39/395&N; - A61K39/395&P; - A61K39/395&T; A61P35/00; - C12M1/00&A; C12N15/00&A; - C12N15/00&F; C12N15/00&H; - C12N15/09&200; - C12N15/113&130Z; - C12N15/115&Z; C12N15/55; - C12N9/16&C; - C12Q1/68&A+ZNA; - C12Q1/6837&Z+ZNA; - C12Q1/6886&Z; - G01N33/50&T; - G01N33/53&D; G01N33/574; - G01N33/574&A
FT	- 4B029/AA07; 4B029/CC01; 4B029/CC02; 4B029/CC08; 4B029/FA15; 4B050/CC10; 4B050/DD11; 4B050/LL01; 4B050/LL03; 4B063/QA01; 4B063/QA13; 4B063/QA18; 4B063/QA19; 4B063/QQ02; 4B063/QQ03; 4B063/QQ08;

4B063/QQ42; 4B063/QQ52;
4B063/QR13; 4B063/QR32;
4B063/QR35; 4B063/QR55;
4B063/QR62; 4B063/QS02;
4B063/QS25; 4B063/QS32;
4B063/QX01; 4B063/QX02;
4C085/AA13; 4C085/AA14;
4C085/CC23; 4C085/EE01

PA - (A)
KONINKLIJKE PHILIPS NV; UNIV
COURT OF THE UNIV OF
GLASGOW

TI - (A)
PHOSPHODIESTERASE 4D7 AS
MARKER OF MALIGNANT
HORMONE SENSITIVE
PROSTATIC **CANCER**

AB - (A)
PROBLEM TO BE SOLVED: To
provide a novel and effective
alternative diagnostic
perspective for
detecting, **monitoring** and
predicting prostatic **cancer**, in
particular, malignant
hormone sensitive
prostatic **cancer**. SOLUTION:
The present invention relates
to a method for using
phosphodiesterase 4D7
(PDE4D7) as a diagnostic
marker for malignant
hormone sensitive
prostatic **cancer**, where the
expression of the marker is
increased when compared to
the expression in normal
tissue or benign **prostate**
tumor tissue in malignant
hormone sensitive
prostatic **cancer** tissues. The
present invention also relates
to a composition for
diagnosing,
detecting, **monitoring** or
prognosticating malignant
hormone sensitive
prostatic **cancer**, and a
diagnostic kit comprising the
composition, a detection
method corresponding to the
diagnostic kit, a method
allowing to discriminate

between benign and malignant hormone sensitive prostatic cancers, and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant hormone sensitive prostatic **cancer** as well as an immunoassay for stratifying an individual with such prostatic **cancer**. The present invention further provides pharmaceutical compositions and their use for the treatment of malignant hormone sensitive prostatic **cancer**.SELECTED
DRAWING: Figure 4

16/187 © EPODOC / EPO

PN - [US2017350896](#) A1 20171207

PR - US201715682224
20170821; US201414412235
20141231; WO2013US48863
20130701; US201261667040P
20120702

AP - US201715682224 20170821

DT - **

CTNP - || STSE (A1)
[A] - Xu et al. (Sci. Rep. 2015
May 5; 5: 10006; pp. 1-7)
[A] - Perner et al. (Hum.
Pathol. 2007 May; 38 (5): 696-
701)
[A] - Kirby et al. (PLoS One.
2012; 7 (4): e35976, pp. 1-10)
[A] - Yates et al. (Prostate.
2012 Sep 1; 72 (12): 1382-8)
[A] - Ben Jemaa et al. (Cell.
Biol. Int. 2013 May; 37 (5):
464-70)
[A] - Okegawa et al. (J. Urol.
2008 Oct; 180 (4): 1342-7)
[A] - Ma et al. (Cancer Cell.
2004 Jun; 5 (6): 607-16)
[A] - Doyen et al. (Crit. Rev.
Oncol. Hematol. 2012 Mar; 81
(3): 241-56)
[A] - Miyamoto et al.



(Cancer Discov. 2012 Nov; 2
(11): 995-1003)
[A] - Evans et al. (Proc. Natl.
Acad. Sci. USA. 2011 Jun 7;
108 (23): 9578-82)
[A] - Goodman et al. (Clin.
Genitourin. Cancer. 2011 Sep;
9 (1): 31-8)

CCI - [A61K31/167](#) ; [A61K31/496](#) ;
[A61K31/58](#) ; [G01N33/57434](#)

CCA - [G01N2333/705](#)

CI - A61K31/167 (EP, US)
- A61K31/496 (EP, US)
- A61K31/58 (EP, US)
- C12Q1/6886 (US)
- G01N33/57434 (EP, US)

CA - A61K2039/505 (US)
- C12Q2600/106 (US)
- C12Q2600/112 (US)
- G01N2333/705 (EP, US)

PA - MASSACHUSETTS GEN
HOSPITAL [US]

TI - DIAGNOSIS AND **MONITORING**
TREATMENT OF **PROSTATE**
CANCER

AB - Provided herein are assays
and methods related to
determining a ratio of
expression levels of
PSA/PSMA or determining the
expression level of PSMA in
circulating tumor cells for
diagnosis and/or for the
purpose of **monitoring**
treatment efficacy
for **prostate** cancers that are
likely hormone resistant.

17/187 © EPODOC / EPO


PN - [CN107267482](#) A 20171020

PR - EP20090159960
20090512; CN20108033823
20100511

AP - CN201710192366 20100511

DT - I

CT - || STSE (A)
[WO03044170](#) A2 20030530
[A] (MEMORY PHARM CORP
[US], et al)
[A] 1-21



* 全文 *;
[CN1532292](#) A 20040929
 [A] (HOFFMANN LA ROCHE
 [CH])
 [A] 1-21
 * 全文 *;
[CN1771329](#) A 20060510
 [X] (HOFFMANN LA ROCHE
 [CH])
 [X] 1-21
 * 对比文件1摘要、对比文件1
 权利要求1-6、说明书第12页
 *

- CTNP - || STSE (A)
 [A] - Daguang Wang ET AL,
 "Cloning and characterization
 of novel PDE4D isoforms
 PDE4D6 and PDE4D7",
 《cellular signalling》
 [A] 1-21
 * 第883-891页 *
- CCI - [A61P13/08](#) ; [A61P35/00](#) ;
[A61P43/00](#) ; [C12N9/16](#) ;
[C12N15/1137](#) ; [C12N15/115](#) ;
[C12Q1/44](#) ; [C12Q1/6886](#) ;
[C12Y301/04017](#) ;
[G01N33/57434](#)
- CCA - [C12N2310/113](#) ;
[C12N2310/14](#) ;
[C12N2310/141](#) ;
[C12N2310/16](#) ;
[C12Q2600/106](#) ;
[C12Q2600/112](#) ;
[G01N2800/52](#) ; [Y10S436/813](#)
- CI - A61P13/08 (EP)
 - A61P35/00 (EP)
 - A61P43/00 (EP)
 - C12N9/16 (EP, CN, KR)
 - C12N15/1137 (EP, CN, KR)
 - C12N15/115 (EP, CN, KR)
 - C12Q1/44 (EP, CN)
 - C12Q1/6886 (EP, CN, KR, RU)
 - C12Y301/04017 (EP, CN)
 - G01N33/57434 (EP, CN, KR)
 - G01N33/68 (US)
 - G01N33/6893 (KR)
- CA - C12N2310/113 (EP, CN)
 - C12N2310/14 (EP, CN)
 - C12N2310/141 (EP, CN)
 - C12N2310/16 (EP, CN)

	- C12Q2600/106 (EP, CN, KR) - C12Q2600/112 (EP, CN, KR) - C12Q2600/118 (KR) - G01N2333/916 (CN, US) - G01N2800/52 (EP, KR) - G01N2800/54 (KR, US) - Y10S436/813 (EP, US)
PA	- KONINKL PHILIPS ELECTRONICS NV; UNIV GLASGOW
TI	- Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
AB	- The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone- sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone- sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone- sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone- sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays.; The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone- sensitive prostate cancer as well as an immunoassay for

stratifying an individual with such **prostate cancer**. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive **prostate cancer**.

18/187 © EPODOC / EPO

PN - [JP2017184729](#) A 20171012

PNFP - JP6430560B B2 20181128

PR - EP20090159960 20090512

AP - JP20170046859 20170313

DT - I

CT - || STSE (A)
[WO03044170](#) A2 20030530
 [XY] (MEMORY PHARM CORP [US], et al)
 [XY] 1,19,1-6,8-9,13-18
 * Page37 Line19 - Page38, Pages41-43, Page32 Lines11-14, Page33 Lines5-7, Page35 Lines15-24 *;
[JP2012526544](#) A 20121101 [];
[JP2012526545](#) A 20121101 []

CTNP - || STSE (A)
 [Y] - E.P.Rahrmann, et al, Cancer Research, (20090428), vol. 69, no. 10, ISSN 0003822819, pages 4388 - 4397
 [Y] 1-6,8-9,13-18
 * Whole Document *

CCI - [A61P13/08](#) ; [A61P35/00](#) ;
[A61P43/00](#) ; [C12N9/16](#) ;
[C12N15/1137](#) ; [C12N15/115](#) ;
[C12Q1/44](#) ; [C12Q1/6886](#) ;
[C12Y301/04017](#) ;
[G01N33/57434](#)

CCA - [C12N2310/113](#) ;
[C12N2310/14](#) ;
[C12N2310/141](#) ;
[C12N2310/16](#) ;
[C12Q2600/106](#) ;
[C12Q2600/112](#) ;
[G01N2800/52](#) ; [Y10S436/813](#)

CI - A61P13/08 (EP)
 - A61P35/00 (EP)
 - A61P43/00 (EP)



	- C12N9/16 (EP, CN, KR) - C12N15/1137 (EP, CN, KR) - C12N15/115 (EP, CN, KR) - C12Q1/44 (EP, CN) - C12Q1/6886 (EP, CN, KR, RU) - C12Y301/04017 (EP, CN) - G01N33/57434 (EP, CN, KR) - G01N33/68 (US) - G01N33/6893 (KR)
CA	- C12N2310/113 (EP, CN) - C12N2310/14 (EP, CN) - C12N2310/141 (EP, CN) - C12N2310/16 (EP, CN) - C12Q2600/106 (EP, CN, KR) - C12Q2600/112 (EP, CN, KR) - C12Q2600/118 (KR) - G01N2333/916 (CN, US) - G01N2800/52 (EP, KR) - G01N2800/54 (KR, US) - Y10S436/813 (EP, US)
FI	- A61K31/7088; A61K38/46; A61K39/395&E; A61K39/395&T; A61K45/00; A61K48/00; A61P13/08; A61P35/00; A61P43/00&111; C12M1/00&A; C12N15/00&A; C12N15/55; C12Q1/68&A+ZNA; C12Q1/6813&Z+ZNA; C12Q1/6886&Z; G01N33/53&M; G01N33/573&A; G01N33/573&B; G01N33/574&A; G01N37/00&102
FT	- 4B029/AA07; 4B029/AA08; 4B029/BB20; 4B029/CC08; 4B029/FA01; 4B029/FA15; 4B063/QA01; 4B063/QA19; 4B063/QQ42; 4B063/QQ53; 4B063/QR32; 4B063/QR55; 4B063/QR62; 4B063/QR82; 4B063/QS25; 4B063/QX02; 4C084/AA02; 4C084/AA03; 4C084/AA13; 4C084/AA17; 4C084/BA01; 4C084/BA08; 4C084/BA22; 4C084/BA44; 4C084/CA18; 4C084/CA53; 4C084/DC22; 4C084/MA13; 4C084/MA24; 4C084/MA37;

4C084/MA52; 4C084/MA55;
 4C084/MA59; 4C084/MA60;
 4C084/MA66; 4C084/NA14;
 4C084/ZA812; 4C084/ZB262;
 4C084/ZC192; 4C084/ZC202;
 4C085/AA13; 4C085/AA14;
 4C085/AA16; 4C085/BB01;
 4C085/BB31; 4C085/BB41;
 4C085/BB43; 4C085/BB44;
 4C085/CC02; 4C085/CC22;
 4C085/CC23; 4C085/EE01;
 4C085/GG01; 4C085/GG02;
 4C085/GG03; 4C085/GG04;
 4C085/GG05; 4C085/GG06;
 4C085/GG08; 4C085/GG10;
 4C086/AA01; 4C086/AA02;
 4C086/EA16; 4C086/MA01;
 4C086/MA04; 4C086/NA14;
 4C086/ZA81; 4C086/ZB26

PA - (A)
 KONINKLIJKE PHILIPS NV; UNIV
 COURT OF THE UNIV OF
 GLASGOW

TI - (A)
 PHOSPHODIESTERASE 4D7
 AS **PROSTATE CANCER** MARKER

AB - (A)
 PROBLEM TO BE SOLVED: To
 provide methods for
 detecting,
 diagnosing, **monitoring** and
 prognosticating **prostate**
cancer. SOLUTION: A diagnosis
 kit comprising a reagent to
 detect the expression level of
 phosphodiesterase 4D7
 (PDE4D7) which is used as a
 marker for diagnosing,
 detecting, **monitoring** or
 prognosticating **prostate**
cancer or the progression
 of **prostate cancer**. A
 diagnosing kit in which
 PDE4D7 is used as a marker
 for discriminating hormone
 sensitive **prostate cancer** and
 hormone refractory **prostate**
cancer. The reagent comprises
 a nucleic acid affinity ligand
 and/or peptide affinity ligand
 to a PDE4D7 expression
 product or PDE4D7 protein,
 the ligand is preferably

modified to function as a contrast medium, and the ligand may be a set of oligonucleotides specific for the PDE4D7 expression product, an aptamer specific for the PDE4D7 expression product or PDE4D7 protein, an antibody or antibody variant specific to PDE4D7 protein. SELECTED DRAWING: Figure 11

19/187 © EPODOC / EPO

PN - [US2017136012](#) A1 20170518

PNFP - US9968600 B2 20180515

PR - US201715420283
20170131; US201514947345
20151120; US201414173588
20140205; US201361831823P

20130606; US201361813122P
20130417


AP - US201715420283 20170131

DT - **

CCI - [A61K31/496](#) ; [A61K31/519](#) ;
[A61K31/58](#) ; [A61K33/24](#) ;
[A61K45/06](#) ; [A61P3/00](#) ;
[A61P13/08](#) ; [A61P31/00](#) ;
[A61P31/10](#) ; [A61P35/00](#)

CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K31/519](#) , [A61K2300/00](#) ,
INV
- [A61K31/58](#) , [A61K2300/00](#) ,
INV
- [A61K33/24](#) , [A61K2300/00](#) ,
INV

CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)
- A61K31/58 (EP, KR, MX, US)
- A61K33/24 (EP, KR, MX, US)
- A61K45/06 (EP, KR, MX, US)
- A61P3/00 (EP)
- A61P13/08 (EP)
- A61P31/00 (EP)
- A61P31/10 (EP)
- A61P35/00 (EP, KR)



	- G01N33/57484 (KR, MX, US)
CA	- A61K2300/00 (KR)
	- G01N2333/96455 (KR, MX, US)
CL	- A61K31/496, A61K2300/00, INV (EP, US)
	- A61K31/519, A61K2300/00, INV (EP, US)
	- A61K31/519, A61K2300/00, A61K31/496, A61K2300/00% 2, A61K33/24, A61K2300/00% 3, A61K31/58, A61K2300/00% 4, INV (MX)
	- A61K31/58, A61K2300/00, INV (EP, US)
	- A61K33/24, A61K2300/00, INV (EP, US)
PA	- (A1 B2) HEDGEPATH PHARMACEUTICALS INC [US]
TI	- (A1) TREATMENT AND PROGNOSTIC MONITORING OF NON-CANCEROUS PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
	- (B2) Treatment and prognostic monitoring of non- cancerous proliferation disorders using hedgehog pathway inhibitors
AB	- (A1 B2) The present invention concerns methods for treating a proliferation disorder, such as prostate cancer , basal cell carcinoma, lung cancer , and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

20/187 © EPODOC / EPO

PN	- US2017136011 A1 20170518	
PNFP	- US9962381 B2 20180508	
PR	- US201715420247	

20170131; US201514947305
20151120; US201414173588
20140205; US201361831823P

20130606; US201361813122P
20130417

AP - US201715420247 20170131

DT - **

CT - || R141 (A1)
[US2008260835](#) A1 20081023
[] (HAYES DAVID [AU], et al)
- || STSE (B2)
[US2008260835](#) A1 20081023
[] (HAYES DAVID [AU], et al)

CCI - [A61K31/496](#) ; [A61K31/519](#) ;
[A61K31/58](#) ; [A61K33/24](#) ;
[A61K45/06](#) ; [A61P3/00](#) ;
[A61P13/08](#) ; [A61P31/00](#) ;
[A61P31/10](#) ; [A61P35/00](#)

CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K31/519](#) , [A61K2300/00](#) ,
INV
- [A61K31/58](#) , [A61K2300/00](#) ,
INV
- [A61K33/24](#) , [A61K2300/00](#) ,
INV

CI - A61K9/0053 (KR, MX, US)
- A61K9/4866 (KR, MX, US)
- A61K31/496 (EP, KR, MX, US)
- A61K31/519 (EP, KR, MX, US)
- A61K31/58 (EP, KR, MX, US)
- A61K33/24 (EP, KR, MX, US)
- A61K45/06 (EP, KR, MX, US)
- A61P3/00 (EP)
- A61P13/08 (EP)
- A61P31/00 (EP)
- A61P31/10 (EP)
- A61P35/00 (EP, KR)
- G01N33/57484 (KR, MX, US)


CA - A61K2300/00 (KR)
- G01N2333/96455 (KR, MX, US)

CL - A61K31/496, A61K2300/00,
INV (EP, US)
- A61K31/519, A61K2300/00,
INV (EP, US)
- A61K31/519, A61K2300/00,
A61K31/496, A61K2300/00%
2, A61K33/24, A61K2300/00%

3, A61K31/58, A61K2300/00%
4, INV (MX)
- A61K31/58, A61K2300/00,
INV (EP, US)
- A61K33/24, A61K2300/00,
INV (EP, US)
PA - (A1 B2)
HEDGEPATH
PHARMACEUTICALS INC [US]
TI - (A1)
TREATMENT AND
PROGNOSTIC **MONITORING**
OF CANCEROUS
PROLIFERATION DISORDERS
USING HEDGEHOG PATHWAY
INHIBITORS
- (B2)
Treatment and
prognostic **monitoring** of
cancerous proliferation
disorders using Hedgehog
pathway inhibitors
AB - (A1 B2)
The present invention
concerns methods for treating
a proliferation disorder, such
as **prostate cancer**, basal cell
carcinoma, lung **cancer**, and
other cancers, using an
inhibitor of the Hedgehog
pathway (HhP); and methods
for **monitoring** subjects
undergoing such treatments
based on biomarkers and
other criteria predictive of
efficacy.

21/187 © EPODOC / EPO

PN - [JP2017043634](#) A 20170302
PR - US201161551195P 20111025
AP - JP20160231469 20161129
DT - I
CCI - [A61B5/4381](#) ; [A61B5/4833](#) ;
[A61K51/1072](#) ; [A61P13/08](#) ;
[A61P35/00](#) ; [A61P35/04](#) ;
[A61P43/00](#) ; [G01N33/57434](#)
CCA - [G01N2800/52](#)
CI - A61B5/4381 (EP, CN, US)
- A61B5/4833 (EP, CN, US)
- A61K51/1018 (US)



	- A61K51/1072 (EP, CN, US)
	- A61P13/08 (EP)
	- A61P35/00 (EP)
	- A61P35/04 (EP)
	- A61P43/00 (EP)
CA	- G01N33/57434 (EP, CN, US)
FI	- G01N2800/52 (EP, CN, US)
	- A61K31/4166; A61K31/4439; A61K31/704; A61K31/713; A61K37/48; A61K38/02; A61K38/43; A61K39/00&H; A61K39/395&T; A61K43/00; A61K45/00; A61K49/00; A61K49/00&A; A61K49/00&C; A61K49/02&B; A61K49/02&C; A61K49/06; A61K49/08; A61K49/14; A61K49/16; A61K51/00; A61K51/00&100; A61K51/00&200; A61K51/02&200; A61K51/08&200; A61K51/10&200; A61P13/08; A61P35/00; A61P35/04; A61P43/00&123; C07K16/18; C12N15/00&A; C12N15/00&A+ZNA; C12N15/07&100; C12P21/08; G01N33/53&D; G01N33/534; G01N33/574&A; G01N33/574&D
FT	- 4B064/AG27; 4B064/DA01; 4B064/DA13; 4C084/AA02; 4C084/AA12; 4C084/AA17; 4C084/AA19; 4C084/BA03; 4C084/BA44; 4C084/DC01; 4C084/MA13; 4C084/MA16; 4C084/MA22; 4C084/MA28; 4C084/MA43; 4C084/MA52; 4C084/MA55; 4C084/MA56; 4C084/MA57; 4C084/MA58; 4C084/MA59; 4C084/MA60; 4C084/MA63; 4C084/MA66; 4C084/NA05; 4C084/NA13; 4C084/NA15; 4C084/ZA81; 4C084/ZB261; 4C084/ZC102; 4C085/AA02; 4C085/AA06; 4C085/AA14; 4C085/AA19; 4C085/AA26; 4C085/CC23; 4C085/EE01; 4C085/EE03; 4C085/GG01; 4C085/GG02; 4C085/GG03; 4C085/GG04; 4C085/GG05; 4C085/GG06;

4C085/GG08; 4C085/GG10;
 4C085/HH01; 4C085/HH03;
 4C085/HH07; 4C085/KA03;
 4C085/KA29; 4C085/KB02;
 4C085/KB07; 4C085/KB09;
 4C085/KB10; 4C085/KB12;
 4C085/KB15; 4C085/KB18;
 4C085/KB82; 4C085/LL18;
 4C086/AA01; 4C086/BC38;
 4C086/EA10; 4C086/EA16;
 4C086/GA07; 4C086/GA08;
 4C086/NA05; 4C086/NA13;
 4C086/ZA81; 4C086/ZB26;
 4H045/AA11; 4H045/AA30;
 4H045/BA10; 4H045/CA40;
 4H045/DA75; 4H045/DA76;
 4H045/EA20; 4H045/EA50

- PA - MEMORIALSLOAN-KETTERING
CANCER CENTER
- TI - FREE PSA ANTIBODIES AS
DIAGNOSTICS, PROGNOSTICS
AND THERAPEUTICS
FOR **PROSTATE CANCER**
- AB - PROBLEM TO BE SOLVED: To
provide free PSA antibodies
as diagnostics, prognostics
and therapeutics for **prostate
cancer**. SOLUTION: The present
invention provides methods
of **monitoring** and measuring
tumor-associated free PSA
("fPSA") with antibody
polypeptides as an indication
of androgen receptor
signaling. In a particular
embodiment, the methods
may be used to assess the
efficacy of anti-androgen
and/or general anti-**cancer**
treatments. The present
invention also provides
various methods and
compositions relating to
antibodies that are specific
for tumor-associated or
intratumoral fPSA. For
example, the present
invention provides
compositions, including
pharmaceutical
compositions, comprising
anti-fPSA antibodies, or
fragments or characteristic

portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions. SELECTED DRAWING: None

22/187 © EPODOC / EPO

PN - [US2016074392](#) A1 20160317

PR - US201514947305
20151120; US201414173588
20140205; US201361831823P

20130606; US201361813122P
20130417

AP - US201514947305 20151120


DT - **

CT - || R141 (A1)
[US2008260835](#) A1 20081023
[] (HAYES DAVID [AU], et al)

CTNP - || R141 (A1)
[] - Stella, Valentino J,
Expert Opinion of Therapeutic
Patents, Prodrugs as
therapeutics, 2004 14(3): 277-
280.
[] - Wolff et al. (Burger's
Medicinal Chemistry, 5th Ed.,
Vol. 1, pgs. 975-977, 1994)
[] - Testa, Bernard,
Biochemical Pharmacology,
Prodrug Research: futile or
fertile? 68 (2004) 2097-2106
[] - Ettmayer, Peter,
Medicinal Chemistry, Lessons
Learned from Marketed and
Investigational Prodrugs, 47
(10) (2004) 2394-2404

CCI - [A61K31/496](#) ; [A61K31/519](#) ;
[A61K31/58](#) ; [A61K33/24](#) ;
[A61K45/06](#) ; [A61P3/00](#) ;
[A61P13/08](#) ; [A61P31/00](#) ;
[A61P31/10](#) ; [A61P35/00](#)

CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K31/519](#) , [A61K2300/00](#) ,
INV
- [A61K31/58](#) , [A61K2300/00](#) ,
INV
- [A61K33/24](#) , [A61K2300/00](#) ,



	INV
CI	- A61K9/0053 (KR, MX, US) - A61K9/4866 (KR, MX, US) - A61K31/496 (EP, KR, MX, US) - A61K31/519 (EP, KR, MX, US) - A61K31/58 (EP, KR, MX, US) - A61K33/24 (EP, KR, MX, US) - A61K45/06 (EP, KR, MX, US) - A61P3/00 (EP) - A61P13/08 (EP) - A61P31/00 (EP) - A61P31/10 (EP) - A61P35/00 (EP, KR) - G01N33/57484 (KR, MX, US)
CA	- A61K2300/00 (KR) - G01N2333/96455 (KR, MX, US)
CL	- A61K31/496, A61K2300/00, INV (EP, US) - A61K31/519, A61K2300/00, INV (EP, US) - A61K31/519, A61K2300/00, A61K31/496, A61K2300/00% 2, A61K33/24, A61K2300/00% 3, A61K31/58, A61K2300/00% 4, INV (MX) - A61K31/58, A61K2300/00, INV (EP, US) - A61K33/24, A61K2300/00, INV (EP, US)
PA	- HEDGEPATH PHARMACEUTICALS INC [US]
TI	- TREATMENT AND PROGNOSTIC MONITORING OF PROLIFERATION DISORDERS USING HEDGEHOG PATHWAY INHIBITORS
AB	- The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

23/187 © EPODOC / EPO

PN - [WO2016011265](#) A2 20160121

PNFP - WO2016011265 A3 20161117

PR - US201462025588P 20140717

AP - WO2015US40771 20150716

DT - *; Rep

CT - |US| ISR (A3)

[US2014086909](#) A1 20140327

[A] (LU KUN PING [US], et al)

[A] 1-5, 20-23

* ; paragraphs [0008], [0074]

-[0084] *;

[XP055328461](#) A[A];

[WO2006028576](#) A2

20060316 [A] (VERNALIS PLC

[GB], et al)

[A] 1-5, 20-23

* ; page 4, lines 12-16; page 5,

lines 23-26; page 7, lines 11-

22; page 8, lines 19-33 *;

[WO2007133702](#) A2

20071122 [A] (CELL

SIGNALING TECHNOLOGY INC

[US], et al)

[A] 1-5, 20-23

* ; page 17, lines 18-21; page

32, lines 25-29 *;

[WO2012162698](#) A1

20121129 [A] (BETH ISRAEL

HOSPITAL [US], et al)

[A] 1-5, 20-23

* ; abstract *;

[US2006074222](#) A1 20060406

[A] (LU KUN P [US], et al)

[A] 1-5, 20-23

* ; abstract *;

[XP055328468](#) A[A]

CTNP - |US| ISR (A3)

[A] - JAGER, M et al.,

"Sequence Determinants Of

Thermodynamic Stability In A

WW Domain: An All-[Beta]-

Sheet Protein.", Protein Sci.,

(20090800), vol. 18, no. 8,

pages 1806 - 1813,

XP055328461

[A] 1-5, 20-23

* ; page 1809, table 1; DOI:

10.1002/pro.172. *

[A] - MA, SL et al., "A

Functional Polymorphism In

PIN1 That Prevents Its


Suppression By AP 4 Is
 Associated With Delayed
 Onset Of Alzheimer's
 Disease.", Neurobiol Aging.,
 (20120400), vol. 33, no. 4,
 pages 804 - 813,
 XP055328468
 [A] 1-5, 20-23
 * 10.1016/j.neurobiolaging.
 2010.05.018 *

CCI	- A61K31/203 ; C12Q1/6883
CCA	- C12Q2600/158
CI	- A61K9/0019 (US) - A61K9/06 (US) - A61K31/203 (EP, US) - C12Q1/6883 (EP, US) - C12Q1/6886 (US)
CA	- C12Q2600/156 (US) - C12Q2600/158 (EP, US)
PA	- (A2) BETH ISRAEL HOSPITAL [US] - (A3) BETH ISRAEL DEACONESS MEDICAL CT INC [US]
TI	- (A2 A3) BIOMARKERS FOR PIN1- ASSOCIATED DISORDERS
AB	- (A2 A3) Biomarkers and driver mutations for diagnosis and prognosis of Pin 1 - associated diseases are disclosed. In one embodiment, the methods for diagnosis of Pin 1 - associated diseases may include detecting the level of Pin1 to stage abnormal cell growth, such as breast or prostate cancer . In another embodiment, the methods include evaluating the efficacy of a treatment of abnormal cell growth, such as cancer , by monitoring the levels of Pin1. In another embodiment, the methods include using driver mutations to determine the pharmacogenetics of abnormal cell growth, such

as **cancer**. In the present disclosure, elevated active monomeric Pin1 levels may be detected by Pin1 biomarkers, which may include Pin1 Q33K or E100D driver mutations, Pin1 protein or transcript overexpression, dephosphorylation of Pin1 on Ser71, dephosphorylation of S16, phosphorylation of S65, phosphorylation of S138, deacetylation of Pin1 on K13 and deacetylation of K46, and/or desumoylation of Pin1 on K6 and desumolation of K63, among others.

24/187 © EPODOC / EPO


PN - [US2016002351](#) A1 20160107
 PR - GB20130003308
 20130225; WO2014GB50549
 20140224
 AP - US201414769980 20140224
 DT - **
 CT - || R141 (A1)
[WO2009028521](#) A1 20090305 [
] (ONCOTHERAPY SCIENCE INC
 [JP], et al)
 CCI - [A61K39/39558](#) ; [A61P15/00](#)
 CCA - [A61K2039/572](#)
 CI - A61K39/39558 (EP)
 - A61K47/6851 (EP)
 - A61K47/6871 (EP)
 - A61K51/1045 (US)
 - A61K51/1075 (US)
 - A61P15/00 (EP)
 - C07K16/2809 (US)
 - C07K16/30 (US)
 - C07K16/40 (US)
 - G01N33/5748 (US)
 CA - A61K2039/572 (EP)
 - C07K2317/31 (US)
 - G01N2333/948 (US)
 - G01N2800/56 (US)
 PA - OXFORD BIOTHERAPEUTICS LTD
 [GB]
 TI - INACTIVEN-ACETYLATED-ALPHA-



LINKED ACIDIC DIPEPTIDASE-LIKE
PROTEIN 2 (NAALADL2) AS A
THERAPEUTIC AND DIAGNOSTIC
TARGET

- AB - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of **cancer**, such as **prostate cancer**, bladder **cancer**, breast **cancer**, esophagus **cancer**, head and neck **cancer**, colorectal **cancer**, liver **cancer**, lung **cancer**, ovarian **cancer**, gastric **cancer**, uterus **cancer** and pancreatic **cancer**, for **monitoring** the effectiveness of **cancer**, such as **prostate cancer**, bladder **cancer**, breast **cancer**, esophagus **cancer**, head and neck **cancer**, colorectal **cancer**, liver **cancer**, lung **cancer**, ovarian **cancer**, gastric **cancer**, uterus **cancer** and pancreatic **cancer** treatment, and for drug development.

- 25/187 © EPODOC / EPO
- PN - [WO2016102560](#) A1 20160630
- PR - GB20140023127 20141223
- AP - WO2015EP80967 20151222
- DT - *; Rep
- CT - |EP| ISR (A1)
[WO2008075056](#) A1
00000000 [X] (UNIV SURREY [GB]; PANDHA HARDEV [GB]; MORGAN RICHARD GEORGE LEONARD [G])
[X] 1-27
* p13 third par; page 7 - page 17; claims 2,16,35 *;
[XP055071692](#) A[X];
[XP055248422](#) A[T];
[XP055248372](#) A[T];
[XP055248377](#) A[T]
- CTNP - |EP| ISR (A1)
[X] - R. MORGAN ET AL,
"Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer", CLINICAL CANCER RESEARCH,



(20110301), vol. 17, no. 5, doi:
[10.1158/1078-0432.CCR-10-2410](https://doi.org/10.1158/1078-0432.CCR-10-2410), ISSN 1078-0432, pages
1090 - 1098, XP055071692

[X] 1-27

* chapter "EN2 protein
detection - Western blotting";;
figure 3 *

[T] - Anonymous, "Anti-EN2
antibody ab45867",
(20090801), URL: <http://www.abcam.com/en2-antibody-ab45867.html>, (20160208),
XP055248422

[T]

* the whole document *

[T] - N. E. ANNELS ET AL,
"Spontaneous antibodies
against Engrailed-2 (EN2)
protein in patients with
prostate cancer", CLINICAL
ANDEXPERIMENTAL
IMMUNOLOGY, GB,
(20140709), vol. 177, no. 2,
doi:[10.1111/cei.12332](https://doi.org/10.1111/cei.12332), ISSN
0009-9104, pages 428 - 438,
XP055248372

[T]

* the whole document *

[T] - RICHARD MORGAN ET
AL, "Expression of Engrailed-2
(EN2) protein in bladder
cancer and its potential
utility as a urinary diagnostic
biomarker", EUROPEAN
JOURNAL OF CANCER, GB,
(20130601), vol. 49, no. 9, doi:
[10.1016/j.ejca.2013.01.019](https://doi.org/10.1016/j.ejca.2013.01.019),
ISSN 0959-8049, pages 2214 -
2222, XP055248377

[T]


* the whole document *

- CCI - [C07K14/435](#) ; [C07K16/18](#) ;
[C07K16/3069](#) ;
[G01N33/57407](#) ;
[G01N33/57434](#)
- CCA - [A61K38/00](#) ; [C07K2317/33](#) ;
[C07K2317/34](#) ;
[G01N2440/38](#) ;
[G01N2800/52](#) ;
[G01N2800/56](#)
- CI - C07K14/435 (EP)

- C07K16/18 (EP)
 - C07K16/3069 (EP)
 - G01N33/57407 (EP)
 - G01N33/57434 (EP)
 CA - A61K38/00 (EP)
 - C07K2317/33 (EP)
 - C07K2317/34 (EP)
 - G01N2440/38 (EP)
 - G01N2800/52 (EP)
 - G01N2800/56 (EP)
 PA - UNIV SURREY [GB]
 TI - GLYCOSYLATED BIOMARKER
 AB - Bladder **cancer** or **prostate cancer** specific biomarkers comprise a glycosylated form of a protein or polypeptide having the amino acid sequence of the encoded Engrailed-2 (EN2) protein. The glycosylated biomarkers are useful in the treatment, diagnosis, **monitoring** and imaging of bladder **cancer** and prostate **cancer**.

26/187 © EPODOC / EPO

PN - [US2015329912](#) A1 20151119
 PR - US201414652611
 20140103; US201361752135P
 20130113; US201361814480P
 20130422; US201361878648P
 20130917; WO2014US11211
 20140113
 AP - US201414652611 20140103
 DT - **
 CTNP - || R141 (A1)
 [] - <http://www.genecards.org>, ACCESSED 9/16/2016/
 [] - Drake, R.R. et al., â In-Depth Proteomic Analyses of Direct Expressed ProstaticSecretionsâ Journal of Proteome Research 2010, 9, 2109â 2116.
 [] - Principe S. et al., In-depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine. Proteomics. 2013 May;13(10-11): 1667-71
 CCI - [A61K31/167](#) ; [A61K31/337](#) ;



[A61K31/566](#) ; [A61K38/08](#) ;
[G01N33/57434](#)


- CCA - [G01N2800/52](#) ; [G01N2800/56](#)
- CI - A61K31/167 (EP, US)
 - A61K31/337 (EP, US)
 - A61K31/566 (EP, US)
 - A61K38/08 (EP)
 - C12Q1/6886 (US)
 - G01N33/57434 (EP, US)
- CA - C12Q2600/112 (US)
 - C12Q2600/156 (US)
 - C12Q2600/158 (US)
 - G01N2333/4703 (US)
 - G01N2333/4712 (US)
 - G01N2333/475 (US)
 - G01N2333/705 (US)
 - G01N2800/52 (EP, US)
 - G01N2800/56 (EP, US)
- PA - UNIV EMORY [US]
- TI - BIOMARKERS IN **CANCER**,
 METHODS, AND SYSTEMS RELATED
 THERETO
- AB - This disclosure relates
 biomarkers of **cancer**, e.
 g. **prostate cancer**. The
 biomarkers may be altered
 expression of nucleic acids,
 mutations, or proteins encoded
 therefrom. In certain
 embodiments, the disclosure
 relates to methods for diagnosing
 pro-state **cancer**, methods of
 distinguishing between less
 aggressive and high
 aggressive **prostate cancer**,
 methods of determining
 predisposition to recurrence
 of **prostate cancer**, methods
 of **monitoring**
 progression/regression
 of **prostate cancer**, methods of
 assessing efficacy of
 compositions for
 treating **prostate cancer**, and
 methods of screening
 compositions for activity in
 modulating biomarkers
 of **prostate cancer**.

PN	- NZ615915 A 20150828	
PR	- WO2012GB00285 20120328; GB20110005129 20110328	
AP	- NZ20120615915 20120328	
DT	- I	
CCI	- A61P35/00 ; A61P43/00 ; C07K14/705 ; C12N15/1135 ; C12N15/1138 ; G01N33/57415 ; G01N33/57423 ; G01N33/57434	
CCA	- C12N2310/14 ; G01N2800/52	
CI	- A61P35/00 (EP) - A61P43/00 (EP) - C07K14/47 (US) - C07K14/705 (EP, US) - C07K16/18 (US) - C12N15/113 (US) - C12N15/1135 (EP, US) - C12N15/1138 (EP, US) - G01N33/57415 (EP, US) - G01N33/57423 (EP, US) - G01N33/57434 (EP, US) - G01N33/57492 (US)	
CA	- C12N2310/14 (EP, US) - G01N2800/52 (EP, US)	
PA	- HOX THERAPEUTICS LTD	
TI	- Compositions and methods for treating, diagnosing and monitoring disease	
AB	- Disclosed is the use of a therapeutically effective amount of a composition which inhibits the expression of the TMEM92 gene or which inhibits the function of the TMEM92 protein, in the manufacture of a medicament for the treatment of cancer . Also disclosed is a method for diagnosing cancer in a patient or for identifying a patient at risk of developing cancer , the method comprising: (a) determining an amount of a biomarker in a sample obtained from a	

patient, the biomarker comprising:- (i) a nucleic acid sequence comprising SEQ ID NO:1, or a functional fragment/variant that has at least about 70% nucleic acid sequence identity with SEQ ID NO:1, or a nucleic acid molecule which comprises said nucleic acid sequence; or (ii) an amino acid sequence comprising SEQ ID NO:2, or a functional fragment/variant that has at least about 70% amino acid sequence identity with SEQ ID NO:2, or an amino acid molecule which comprises said amino acid sequence, optionally wherein the biomarker is a **cancer** biomarker selected from a **prostate cancer** biomarker, a non-small cell lung **cancer** biomarker and breast **cancer** biomarker.

28/187 © EPODOC / EPO


PN - [CN104884960](#) A 20150902
PR - WO2013NZ00115
20130703; US201261668395P
20120705
AP - CN20138045922 20130703
DT - I
CCI - [A61K31/496](#) ; [A61K38/193](#) ;
[A61K45/06](#) ; [A61P35/00](#) ;
[G01N33/57415](#) ;
[G01N33/57434](#)
CCA - [G01N2800/52](#)
CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K38/193](#) , [A61K2300/00](#) ,
INV
CI - A61K31/496 (EP, CN)
- A61K31/497 (US)
- A61K38/193 (EP, CN, US)
- A61K45/06 (EP, CN)
- A61P35/00 (EP)
- G01N33/5047 (US)
- G01N33/57415 (EP, CN)



	- G01N33/57434 (EP, CN)
CA	- G01N2800/52 (EP, CN)
CL	- A61K31/496, A61K2300/00, INV (EP)
	- A61K38/193, A61K2300/00, INV (EP)
PA	- CALDERAHEALTHLTD
TI	- Methods for determining personalized treatment compositions for prostate cancer and breast cancer
AB	- The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer , such as prostate or breast cancer , in a patient wherein the treatment composition includes administering a combination of at least two components selected from immune cell activating agents, such as GM- CSF, and antigen display enhancing agents, such as ketoconazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.

29/187 © EPODOC / EPO

PN	- US2015168413 A1 20150618
PNFP	- US9766244 B2 20170919
PR	- US201314412235 20130701; US201261667040P 20120702; WO2013US48863 20130701
AP	- US201314412235 20130701
DT	- **
CTNP	- R141 (A1) [] - Jemaa et al. (J. Immunoassay Immunochem. 2014; 35 (1): 48-59) [] - Morgan et al. (Clin.



	Cancer Res. 2009 Jan 15; 15 (2): 677-83) [] - Pilepich et al. (Int. J. Radiat. Oncol. Biol. Phys. 2005 Apr 1; 61 (5): 1285-90) [] - Elgamal et al. (Semin. Surg. Oncol. 2000 Jan-Feb; 18 (1): 10-6). [] - Yates et al. (Prostate. 2012 Sep 1; 72 (12): 1382-8) [] - Miyamoto et al. (Cancer Discov. 2012 Nov; 2 (11): 995-1003)
	- STSE (B2) [] - Jemaa et al. (J. Immunoassay Immunochem. 2014; 35 (1): 48-59). [] - Morgan et al. (Clin. Cancer Res. Jan. 15, 2009; 15 (2): 677-83). [] - Pilepich et al. (Int. J. Radiat. Oncol. Biol. Phys. Apr. 1, 2005; 61 (5): 1285-90). [] - Elgamal et al. (Semin. Surg. Oncol. Jan.-Feb. 2000; 18 (1): 10-6). [] - Yates et al. (Prostate. Sep. 1, 2012; 72 (12): 1382-8). [] - Miyamoto et al. (Cancer Discov. Nov. 2012; 2 (11): 995-1003).
CCI	- A61K31/167 ; A61K31/496 ; A61K31/58 ; G01N33/57434
CCA	- G01N2333/705
CI	- A61K31/167 (EP, US) - A61K31/496 (EP, US) - A61K31/58 (EP, US) - C12Q1/6886 (US) - G01N33/57434 (EP, US)
CA	- A61K2039/505 (US) - C12Q2600/106 (US) - C12Q2600/112 (US) - G01N2333/705 (EP, US)
PA	- (A1) GEN HOSPITAL CORP [US] - (B2) MASSACHUSETTS GEN HOSPITAL [US]
TI	- (A1) DIAGNOSIS AND MONITORING TREATMENT OF

PROSTRATE **CANCER**

- (B2)
Diagnosis and **monitoring**
treatment of **prostate cancer**

AB

- (A1 B2)
Provided herein are assays
and methods related to
determining a ratio of
expression levels of
PSA/PSMA or determining the
expression level of PSMA in
circulating tumor cells for
diagnosis and/or for the
purpose of **monitoring**
treatment efficacy
for **prostate** cancers that are
likely hormone resistant.

30/187 © EPODOC / EPO

PN - [RU2013123500](#) A 20141127

PNFP - RU2541810 C2 20150220

PR - RU20130123500 20130523

AP - RU20130123500 20130523

DT - I

PA - (C2)
FARM SINTEZ AOZT [RU]

TI - (C2)
METHOD OF
TREATING **PROSTATE CANCER**
WITH USING PROLONGED
PRODRUG OF OCTREOTIDE
ACCOMPANYING SURGICAL OR
DRUG-INDUCED CASTRATION


AB - (C2)
FIELD:medicine.SUBSTANCE:
invention refers to medicine,
particularly to oncurology,
and can be used in the non-
surgical treatment of the
patients suffering early
stages of **prostate** malignant
tumour. A method of
treating **prostate cancer** with
using prolonged prodrug of
octreotide accompanying
surgical or drug-induced
castration involves a)
measuring pre-
therapeutic **prostate**-specific
antigen; b) measuring pre-
therapeutic blood plasma



chromogranin A; c) selecting the patients having high blood chromogranin A of more than 3 nmol/l; d) conducting a therapy with prolonged prodrug of octreotide in a combination with dexamethasone in the selected patients; e) controlling the **prostate**-specific antigen variation every month and **monitoring** a decrease thereof in the patients by measuring it intra-therapeutically according to the stage d); the therapeutic efficacy according to the stage d) is evaluated by a therapeutic response, which is accompanied by maximum decrease of the **prostate**-specific antigen.EFFECT: invention enables providing the higher therapeutic efficacy in the patients suffering **prostate cancer** at the different stages.3 cl, 1 tbl, 5 ex

31/187 © EPODOC / EPO


PN - [CA2877872](#) A1 20140109
PR - US201261668395P
20120705; WO2013NZ00115
20130703
AP - CA20132877872 20130703
DT - I
CCI - [A61K31/496](#) ; [A61K38/193](#) ;
[A61K45/06](#) ; [A61P35/00](#) ;
[G01N33/57415](#) ;
[G01N33/57434](#)
CCA - [G01N2800/52](#)
CLC - [A61K31/496](#) , [A61K2300/00](#) ,
INV
- [A61K38/193](#) , [A61K2300/00](#) ,
INV
CI - A61K31/496 (EP, CN)
- A61K31/497 (US)
- A61K38/193 (EP, CN, US)
- A61K45/06 (EP, CN)
- A61P35/00 (EP)
- G01N33/5047 (US)



	- G01N33/57415 (EP, CN)
	- G01N33/57434 (EP, CN)
CA	- G01N2800/52 (EP, CN)
CL	- A61K31/496, A61K2300/00, INV (EP)
	- A61K38/193, A61K2300/00, INV (EP)
PA	- CALDERAHEALTH LTD [NZ]
TI	- METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER
AB	- The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a cancer , such as prostate or breast cancer , in a patient wherein the treatment composition includes administering a combination of at least two components selected from immune cell activating agents, such as GM- CSF, and antigen display enhancing agents, such as ketoconazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for monitoring the efficacy of the treatment composition during a treatment period.

32/187 © EPODOC / EPO

PN	- AU2013285626 A1 20150122
PR	- US201261668395P 20120705; WO2013NZ00115 20130703
AP	- AU20130285626 20130703
DT	- I
CCI	- A61K31/496 ; A61K38/193 ; A61K45/06 ; A61P35/00 ; G01N33/57415 ; G01N33/57434
CCA	- G01N2800/52



- CLC - [A61K31/496](#), [A61K2300/00](#),
INV
- [A61K38/193](#), [A61K2300/00](#),
INV
- CI - A61K31/496 (EP, CN)
- A61K31/497 (US)
- A61K38/193 (EP, CN, US)
- A61K45/06 (EP, CN)
- A61P35/00 (EP)
- G01N33/5047 (US)
- G01N33/57415 (EP, CN)
- G01N33/57434 (EP, CN)
- CA - G01N2800/52 (EP, CN)
- CL - A61K31/496, A61K2300/00,
INV (EP)
- A61K38/193, A61K2300/00,
INV (EP)
- PA - CALDERAHEALTH LTD [NZ]
- TI - Methods for determining
personalized treatment
compositions for **prostate
cancer** and breast **cancer**
- AB - The present disclosure
provides methods for
selecting a treatment
composition, or therapy, for
the treatment of a **cancer**,
such as **prostate** or
breast **cancer**, in a patient
wherein the treatment
composition includes
administering a combination
of at least two components
selected from immune cell
activating agents, such as GM-
CSF, and antigen display
enhancing agents, such as
ketoconazole. Methods for
treating a patient using the
selected treatment
composition are also
provided, together with
methods for **monitoring** the
efficacy of the treatment
composition during a
treatment period.

33/187 © EPODOC / EPO

PN - [WO2014205555](#) A1 20141231

PNFP - WO2014205555 A8 20150129

**

PR - US201361841225P 20130628

AP - WO2014CA00538 20140627

DT - *; Rep

CT - |CA| ISR (A1)
[WO2012068383](#) A2 20120524
 [A] (UNIV MICHIGAN [US], et al);
[US2011136683](#) A1 20110609
 [A] (DAVICIONI ELAI [CA]);
[US2013267443](#) A1 20131010
 [AP] (CHINNAIYAN ARUL [US], et al)

CTNP - |CA| ISR (A1)
 [XP] - CREA, F. ET AL.,
 "Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.",
 ONCOTARGET, (20140206), vol. 5, no. 3, pages 764 - 774

CCI - [A61K31/7088](#) ; [A61K31/713](#) ;
[A61P35/00](#) ; [C12N15/113](#) ;
[C12Q1/6886](#)

CCA - [C12N2310/14](#) ; [C12Q2600/158](#)

CI - A61K31/7088 (EP)
 - A61K31/713 (EP, US)
 - A61P35/00 (EP)
 - C12N15/113 (EP, US)
 - C12Q1/6886 (EP, US)

CA - C12N2310/14 (EP, US)
 - C12Q2600/158 (EP, US)

PA - (A1 A8)
 BRITISH COLUMBIA CANCER AGENCY [CA]

TI - (A1 A8)
 METHODS AND USES FOR DIAGNOSIS AND TREATMENT OF **PROSTATE CANCER**

AB - (A1 A8)
 In an aspect, the invention provides methods and uses of PCAT18 for diagnosing, prognosing, and treatment **monitoring** of **prostate cancer** (PCa) in a subject. In another aspect, methods of treating PCa in a subject by administering an inhibiting agent of PCAT18 are provided. Uses of PCAT18 in

treating PCa in a subject, and pharmaceutical compositions comprising a therapeutic agent effective to reduce the amount of PCAT18 in cancerous **prostate** cells and a pharmaceutically acceptable carrier, are also provided. The transcript of PCAT18 is a long non-coding RNA (lncRNA), whose expression is significantly altered in biological samples obtained from subjects with PCa or at risk of developing PCa compared to normal individuals. Expression of PCAT18 is specific to **prostate** tissue and is elevated in both cancerous **prostate** tissue and blood plasma of subjects with PCa relative to subjects without PCa or patients with other forms of **cancer**.

34/187 © EPODOC / EPO

PN - [JP2014223083](#) A 20141204

PR - US20070963837P 20070807

AP - JP20140155821 20140731

DT - I


CCI - [A61P35/00](#) ; [C12Q1/37](#) ;
[G01N33/573](#) ; [G01N33/574](#)

CCA - [G01N2333/96433](#)

CI - A61P35/00 (EP)
C12Q1/37 (EP)
G01N33/573 (EP)
G01N33/574 (EP)

CA - G01N2333/96433 (EP)

FI - A61K37/02; A61K38/00;
A61K39/395&N; A61K45/00;
A61P35/00; C07K14/47;
C07K16/40; C12N1/15;
C12N1/19; C12N1/21;
C12N15/00&A;
C12N15/00&A+ZNA;
C12N15/13; C12N15/62&Z;
C12N5/00&101; C12N5/16;
C12N9/64&Z; C12P21/08;
C12Q1/37; C12Q1/68&A;
G01N33/15&Z; G01N33/50&Z



FT	- 2G045/AA40; 2G045/CB02; 2G045/DA13; 2G045/DA36; 2G045/FB01; 2G045/FB02; 2G045/FB03; 4B024/AA01; 4B024/AA11; 4B024/AA12; 4B024/BA44; 4B024/BA53; 4B024/CA04; 4B024/DA02; 4B024/EA04; 4B024/GA03; 4B050/CC10; 4B050/DD11; 4B050/LL01; 4B050/LL03; 4B063/QA18; 4B063/QQ44; 4B063/QQ91; 4B063/QQ95; 4B063/QR16; 4B063/QR32; 4B063/QR57; 4B063/QR62; 4B063/QS25; 4B063/QS28; 4B063/QS34; 4B063/QX01; 4B063/QX02; 4B064/AG27; 4B064/CA10; 4B064/CA19; 4B064/CC24; 4B064/DA01; 4B064/DA05; 4B064/DA13; 4B064/DA14; 4B065/AA91X; 4B065/AA91Y; 4B065/AB01; 4B065/AB04; 4B065/AC14; 4B065/BA02; 4B065/CA25; 4B065/CA44; 4C084/AA02; 4C084/AA07; 4C084/AA17; 4C084/BA44; 4C084/DC50; 4C084/NA14; 4C084/ZB261; 4C085/AA14; 4C085/AA16; 4C085/BB11; 4C085/CC02; 4C085/CC23; 4C085/DD88; 4C085/EE01; 4H045/AA10; 4H045/AA11; 4H045/AA20; 4H045/AA30; 4H045/BA10; 4H045/CA40; 4H045/DA76; 4H045/DA89; 4H045/EA28; 4H045/EA31; 4H045/EA50; 4H045/EA51; 4H045/FA74
PA	- OXFORD BIOTHERAPEUTICS LTD; MEDAREX LLC
TI	- MATRIPTASE PROTEIN AND USE THEREOF
AB	- PROBLEM TO BE SOLVED: To provide methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, methods and compositions

for **monitoring** the effectiveness of breast **cancer**, colorectal **cancer**, esophageal **cancer**, gastric **cancer**, **prostate cancer** and uterine **cancer** treatment, and methods and compositions for drug development.SOLUTION: There are provided affinity reagents which are antibodies, antibody fragments thereof or antibody derivatives thereof and can specifically bind to a matriptase stem located on a cell surface and having a specific sequence, and pharmaceutical compositions comprising the reagents.

35/187 © EPODOC / EPO

PN - [CN104040341](#) A 20140910

PNFP - CN104040341B B 20161228

PR - WO2012US61982
 20121025; US201161551195P
 20111025

AP - CN20128063852 20121025

DT - I

CT - || STSE (A)
 [US2006199230](#) A1 20060907
 [Y] (MIKOLAJCZYK STEPHEN D
 [US]);
 [CN101137672](#) A 20080305
 [Y] (DAVID ULMERT [SE]);
 [US6423503](#) B1 20020723
 [A] (MIKOLAJCZYK STEPHEN D
 [US], et al)
 [A] 1-20;
 [US2002001588](#) A1 20020103
 [Y] (SINHA AKHOURI A [US]);
 [US2004101914](#) A1 20040527
 [Y] (PETTERSSON KIM [FI], et al);
 [US2006211059](#) A1 20060921
 [Y] (TANEJA SAMIR S [US]);
 [US2006211059](#) A1 20060921
 [X] (TANEJA SAMIR S [US]);
 [US2010151501](#) A1 20100617
 [A] (MIKOLAJCZYK STEPHEN D
 [US], et al)

CTNP - || STSE (A)
 [A] - 段永顺, "雄激素受体信号
 途径与前列腺癌", 《临床泌尿



外科杂志》, (20010131), vol.
16, no. 1
[A] 1-11

- CCI - [A61B5/4381](#) ; [A61B5/4833](#) ;
[A61K51/1072](#) ; [A61P13/08](#) ;
[A61P35/00](#) ; [A61P35/04](#) ;
[A61P43/00](#) ; [G01N33/57434](#)
- CCA - [G01N2800/52](#)
- CI - A61B5/4381 (EP, CN, US)
- A61B5/4833 (EP, CN, US)
- A61K51/1018 (US)
- A61K51/1072 (EP, CN, US)
- A61P13/08 (EP)
- A61P35/00 (EP)
- A61P35/04 (EP)
- A61P43/00 (EP)
- G01N33/57434 (EP, CN, US)
- CA - G01N2800/52 (EP, CN, US)
- PA - (A)
SLOAN KETTERING INST CANCER
- TI - (A)
Free PSA antibodies as
diagnostics, prognostics and
therapeutics for **prostate cancer**
- AB - (A)
The present invention provides
methods of **monitoring** and
measuring tumor- associated
free PSA ("fPSA") with antibody
polypeptides as an indication
of androgen receptor signaling.
In a particular embodiment, the
methods may be used to assess
the efficacy of anti-androgen
and/or general anti-**cancer**
treatments. The present
invention also provides various
methods and compositions
relating to antibodies that are
specific for tumor- associated
or intratumoral fPSA. For
example, the present invention
provides compositions,
including pharmaceutical
compositions, comprising anti-
fPSA antibodies, or fragments
or characterisitic portions
thereof. The present invention
further provides various
therapeutic and/or diagnostic
methods of using anti-fPSA

antibodies and/or
compositions.

36/187 © EPODOC / EPO

PN - [AU2012328679](#) A1 20140612

PNFP - AU2012328679B B2 20180628
- AU2012328679C C1 20181025

PR - US201161551195P
20111025; WO2012US61982
20121025

AP - AU20120328679 20121025

DT - I

CTNP - || STSE (B2 C1)
[] - K PETTERSON ET AL.
CLINICALCHEMISTRY.,
AMERICAN ASSOCIATION FOR
CLINICALCHEMISTRY,
(199510), vol. 41, no. 10, ISSN
0009-9147, pages 1480 - 1488

CCI - [A61B5/4381](#) ; [A61B5/4833](#) ;
[A61K51/1072](#) ; [A61P13/08](#) ;
[A61P35/00](#) ; [A61P35/04](#) ;
[A61P43/00](#) ; [G01N33/57434](#)

CCA - [G01N2800/52](#)

CI - A61B5/4381 (EP, CN, US)
- A61B5/4833 (EP, CN, US)
- A61K51/1018 (US)
- A61K51/1072 (EP, CN, US)
- A61P13/08 (EP)
- A61P35/00 (EP)
- A61P35/04 (EP)
- A61P43/00 (EP)
- G01N33/57434 (EP, CN, US)

CA - G01N2800/52 (EP, CN, US)


PA - (A1)
SLOAN KETTERING INST CANCER
- (B2)
MEMORIALSLOAN KETTERING
CANCER CENTER
- (C1)
MEMORIALSLOAN KETTERING
CANCER CENTER [US]

TI - (A1 B2 C1)
Free PSA antibodies as
diagnostics, prognostics and
therapeutics for **prostate
cancer**

AB - (A1 B2 C1)
The present invention

provides methods of **monitoring** and measuring tumor- associated free PSA ("fPSA") with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-**cancer** treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor- associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characterisitic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.


37/187 © EPODOC / EPO
 PN - [CA2854059](#) A1 20130510
 PR - EP20110306438
 20111104; WO2012IB56116
 20121102
 AP - CA20122854059 20121102
 DT - I
 CCI - [A61P35/00](#) ; [A61P43/00](#) ;
[C07K16/22](#) ; [C07K16/2863](#) ;
[C07K16/3069](#) ;
[G01N33/57434](#)
 CCA - [C07K2317/73](#) ;
[G01N2333/575](#)
 CI - A61P35/00 (EP)
 - A61P43/00 (EP)
 - C07K16/22 (EP)
 - C07K16/2863 (EP)
 - C07K16/2869 (US)
 - C07K16/3069 (EP)



	- G01N33/54306 (US)
	- G01N33/57434 (EP)
CA	- C07K2317/73 (EP)
	- G01N2333/575 (EP)
PA	- UNIV AIX MARSEILLE [FR]; ASSIST PUBL HOPITAUX MARSEILLE [FR]; CENTRE NAT RECH SCIENT [FR]; INST NAT SANTE RECH MED [FR]
TI	- DIAGNOSTIC AND TREATMENT OF AN ANDROGEN- INDEPENDENT PROSTATE CANCER
AB	- The present invention relates to a method for monitoring the tumor growth of an androgen- independent prostate cancer in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a prostate cancer cell obtained from said subject. The present invention also relates to a pharmaceutical composition comprising an anti-adrenomedullin antagonist antibody and/or at least one anti- adrenomedullin receptor antagonist antibody for treating an androgen- independent prostate cancer .

38/187 © EPODOC / EPO


PN	- CA2853705 A1 20130502
PR	- US201161551195P 20111025; WO2012US61982 20121025
AP	- CA20122853705 20121025
DT	- I
CCI	- A61B5/4381 ; A61B5/4833 ; A61K51/1072 ; A61P13/08 ; A61P35/00 ; A61P35/04 ; A61P43/00 ; G01N33/57434
CCA	- G01N2800/52
CI	- A61B5/4381 (EP, CN, US) - A61B5/4833 (EP, CN, US) - A61K51/1018 (US)



	- A61K51/1072 (EP, CN, US)
	- A61P13/08 (EP)
	- A61P35/00 (EP)
	- A61P35/04 (EP)
	- A61P43/00 (EP)
	- G01N33/57434 (EP, CN, US)
CA	- G01N2800/52 (EP, CN, US)
PA	- SLOAN KETTERING INST CANCER [US]
TI	- FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER
AB	- The present invention provides methods of monitoring and measuring tumor- associated free PSA ("fPSA") with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti- cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor- associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

39/187 © EPODOC / EPO

PN	- WO2014007661 A1 20140109
PR	- US201261668395P 20120705
AP	- WO2013NZ00115 20130703
DT	- **



CT - |AU| ISR (A1)
WO2005046686 A1
 20050526 [A] (CELGENE CORP
 [US], et al);
XP055182348 A[A];
XP055182350 A[A];
XP022338330 A[A];
XP055182351 A[A];
XP009135044 A[A];
WO2007035368 A2
 20070329 [A] (CALIPER LIFE
 SCIENCES INC [US], et al);
XP008175967 A[A];
XP055182361 A[A]

CTNP - |AU| ISR (A1)
 [A] - PFEIFFER, M.J. ET AL.,
 "An in vitro model for
 preclinical testing of
 endocrine therapy
 combinations for prostate
 cancer", THE PROSTATE,
 (2010), vol. 70, pages 1524 -
 1532, XP055182348
 [A] - GARCIA, J.A. ET AL.,
 "Clinical and biological
 effects ofneoadjuvant
 sargramostim and
 thalidomide in patients with
 locally advanced prostate
 carcinoma", CLINICAL CANCER
 RESEARCH, (2008), vol. 14, no.
 10, pages 3052 - 3059,
 XP055182350
 [A] - RYAN, C.J. ET AL., "Phase
 II study of ketoconazole plus
 granulocyte-macrophage
 colony-stimulating factor for
 prostate cancer: effect of
 extent of disease on
 outcome", THE JOURNAL OF
 UROLOGY, (2007), vol. 178,
 pages 2372 - 2377,
 XP022338330
 [A] - KONO, K. ET AL.,
 "Prognostic significance of
 adoptive immunotherapy with
 tumor- associated
 lymphocytes in patients with
 advanced gastric cancer: a
 randomized trial", CLINICAL
 CANCER RESEARCH, (2002),
 vol. 8, pages 1767 - 1771,
 XP055182351

[A] - PINTHUS, J.H. ET AL.,
 "Adoptive immunotherapy of
 prostate cancer bone lesions
 using redirected effector
 lymphocytes", THE JOURNAL
 OF CLINICAL INVESTIGATION,
 (2004), vol. 114, no. 12, pages
 1774 - 1781, XP009135044

[A] - ALBRECHT, H.,
 "Trastuzumab (Herceptin):
 overcoming resistance in
 HER2- overexpressing breast
 cancer models",
 IMMUNOTHERAPY, (2010),
 vol. 2, no. 6, pages 795 - 798,
 XP008175967

[A] - SEKI, N. ET AL., "Strategy
 to augment the efficacy of
 immunotherapy for refractory
 breast cancer: a pilot clinical
 study of adoptive cell therapy
 combined with trastuzumab",
 EUROPEAN JOURNAL OF
 CANCER, (2010), vol. 8, no. 3,
 pages 107 - 108,
 XP055182361


- CCI - [A61K31/496](#) ; [A61K38/193](#) ;
[A61K45/06](#) ; [A61P35/00](#) ;
[G01N33/57415](#) ;
[G01N33/57434](#)
- CCA - [G01N2800/52](#)
- CLC - [A61K31/496](#), [A61K2300/00](#) ,
 INV
 - [A61K38/193](#), [A61K2300/00](#) ,
 INV
- CI - A61K31/496 (EP, CN)
 - A61K31/497 (US)
 - A61K38/193 (EP, CN, US)
 - A61K45/06 (EP, CN)
 - A61P35/00 (EP)
 - G01N33/5047 (US)
 - G01N33/57415 (EP, CN)
 - G01N33/57434 (EP, CN)
- CA - G01N2800/52 (EP, CN)
- CL - A61K31/496, A61K2300/00,
 INV (EP)
 - A61K38/193, A61K2300/00,
 INV (EP)
- PA - CALDERA HEALTH LTD [NZ]
- TI - METHODS FOR DETERMINING

PERSONALIZED TREATMENT
COMPOSITIONS
FOR **PROSTATE CANCER** AND
BREAST CANCER

- AB - The present disclosure provides methods for selecting a treatment composition, or therapy, for the treatment of a **cancer**, such as **prostate** or breast **cancer**, in a patient wherein the treatment composition includes administering a combination of at least two components selected from immune cell activating agents, such as GM-CSF, and antigen display enhancing agents, such as ketoconazole. Methods for treating a patient using the selected treatment composition are also provided, together with methods for **monitoring** the efficacy of the treatment composition during a treatment period.

40/187 © EPODOC / EPO

- PN - [US2014010777](#) A1 20140109
- PNFP - US8784795 B2 20140722
- PR - US201313935355
20130703; US201261668395P
20120705
- AP - US201313935355 20130703
- DT - *; Rep
- CT - || STSE (B2)
[US2009042225](#) A1 00000000
[]
- CTNP - || STSE (B2)
[] - Heppner et al. Tumor heterogeneity: biological implications and therapeutic consequences Cancer Metastasis Review. 1983; 2: 5-23.
[] - Haendler et al. Recent developments in antiandrogens and selective androgen receptor



modulators. Molecular and Cellular Endocrinology. published online Jun. 162011; 352:79-91.

[] - Dreicer et al. Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2005; 23: 82-86.

CCI	- A61K31/496 ; A61K38/193 ; A61K45/06 ; G01N33/57415 ; G01N33/57434
CCA	- G01N2800/52
CLC	- A61K31/496 , A61K2300/00 , INV - A61K38/193 , A61K2300/00 , INV
CI	- A61K31/496 (EP, CN) - A61K31/497 (US) - A61K38/193 (EP, CN, US) - A61K45/06 (EP, CN) - G01N33/5047 (US) - G01N33/57415 (EP, CN) - G01N33/57434 (EP, CN)
CA	- G01N2800/52 (EP, CN)
CL	- A61K31/496, A61K2300/00, INV (EP) - A61K38/193, A61K2300/00, INV (EP)
PA	- (A1) CALDERAHEALTHLTD[NZ] - (B2) CALDERAHEALTHLTD[NZ]; CALDERAHEALTHLTD[NZ]
TI	- (A1) METHODS FOR DETERMINING PERSONALIZED TREATMENT COMPOSITIONS FOR PROSTATE CANCER AND BREAST CANCER - (B2) Methods for determining personalized treatment compositions for prostate cancer and breast cancer
AB	- (A1 B2) The present disclosure

provides methods for selecting a treatment composition, or therapy, for the treatment of a **cancer**, such as **prostate** or breast **cancer**, in a patient wherein the treatment composition includes administering a combination of at least two components selected from two different classes of compounds. Methods for treating a patient using the selected treatment composition are also provided, together with methods for **monitoring** the efficacy of the treatment composition during a treatment period.

41/187 © EPODOC / EPO

PN - [US2013217647](#) A1 20130822

PR - US201113812183
20110727; US20100368434P
20100728; WO2011US45514
20110727

AP - US201113812183 20110727

DT - **

CCI - [G01N33/57434](#)

CCA - [G01N2800/52](#) ; [G01N2800/56](#)


CI - A61K31/685 (US)
- A61K31/7072 (US)
- G01N33/57434 (EP, US)

CA - G01N2800/52 (EP)
- G01N2800/56 (EP)

PA - SHUSTERJEFFREY R [US]; MITCHELL
MATTHEW W [US]; MCDUNN
JONATHAN E [US]; NERI BRUCE [US];
METABOLON INC [US]

TI - Biomarkers for **Prostate Cancer**
and Methods Using the Same

AB - Biomarkers (and suites of
biomarkers) relating to **prostate
cancer** are provided, as well as
methods for using such biomarkers
(ans suites thereof), including early
prediction of **prostate cancer**,
disease grading, target
identification/validation,



and **monitoring** of drug efficacy.

42/187 © EPODOC / EPO

PN - [US2013210900](#) A1 20130815

PNFP - US9982304 B2 20180529

PR - US201113819933
20110906; US20100379875P
20100903; WO2011US0487
20110906

AP - US201113819933 20110906

DT - **

CT - || R141 (A1)
[US2010196426](#) A1 20100805
[] (SKOG JOHAN KARL OLOV
[US], et al)
- || STSE (B2)
[US2010196426](#) A1 20100805
[] (SKOG JOHAN KARL OLOV
[US], et al)

CTNP - || R141 (A1)
[] - Huang et al; Genes
Chromosomes and Cancer,
vol 46, pages 745-750, 2007
[] - Wang et al; Biochem. J.
vol 383, pages 319-325, 2004
[] - Jones et al; Science vol
321, pages 1801-1806, 2008
- || STSE (B2)
[] - Huang et al; Genes
Chromosomes and Cancer,
vol. 46, pp. 745-750, 2007.
[] - Wang et al; Biochem. J.
vol. 383, pp. 319-325, 2004.
[] - Jones et al; Science vol.
321, pp. 1801-1806, 2008.

CCI - [A61K31/7088](#) ; [A61K31/711](#) ;
[C12Q1/6886](#) ; [G01N33/5011](#)

CCA - [C12Q2600/156](#)

CI - A61K31/7088 (EP, US)
- A61K31/711 (EP, US)
- C12Q1/6886 (EP, US)
- G01N33/5011 (EP, US)

CA - C12Q2600/156 (EP, US)

PA - (A1 B2)
VOGELSTEIN BERT [US];
KINZLER KENNETH W [US];
VELCULESCU VICTOR [US];
PAPADOPOULOS NICKOLAS
[US]; JONES SIAN [US]; UNIV
JOHNS HOPKINS [US]

TI	- (A1) ARID1A and PPP2R1A Mutations in Cancer - (B2) ARID1A and PPP2R1A mutations in cancer
AB	- (A1 B2) Two genes, ARID1A (AT-rich interactive domain- containing protein 1A) and PPP2R1A (protein- phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer , diagnosing cancer , contributing to a diagnosis of cancer , confirming a diagnosis of cancer , identifying appropriate treatments for cancer , monitoring treatment of cancer , and evaluating treatment protocols for cancer , including ovarian clear cell carcinoma, breast cancer , colon cancer , gastric cancer , lung cancer , medulloblastoma, pancreatic cancer , and prostate cancer .

43/187 © EPODOC / EPO

PN - [WO2013063312](#) A1 20130502

PR - US201161551195P 20111025


AP - WO2012US61982 20121025

DT - *, Rep

CT - |US| ISR (A1)
[US2006211059](#) A1 20060921
 [X] (TANEJA SAMIR S [US]);
[US2006199230](#) A1 20060907
 [Y] (MIKOLAJCZYK STEPHEN D
 [US]);
[US2004101914](#) A1 20040527
 [Y] (PETTERSSON KIM [FI], et al);
[US2002001588](#) A1 20020103
 [Y] (SINHA AKHOURI A [US])

CCI - [A61B5/4381](#) ; [A61B5/4833](#) ;
[A61K51/1072](#) ; [A61P13/08](#) ;
[G01N33/57434](#)

CCA - [G01N2800/52](#)



CI	- A61B5/4381 (EP, CN, US) - A61B5/4833 (EP, CN, US) - A61K51/1018 (US) - A61K51/1072 (EP, CN, US) - A61P13/08 (EP) - G01N33/57434 (EP, CN, US)
CA	- G01N2800/52 (EP, CN, US)
PA	- SLOAN KETTERING INST CANCER [US]
TI	- FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER
AB	- The present invention provides methods of monitoring and measuring tumor- associated free PSA ("fPSA") with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti- cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor- associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti- fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

44/187	© EPODOC / EPO
PN	- US2013039854 A1 20130214
PNFP	- US9771625 B2 20170926
PR	- US201213559431 20120726; US201161511920P 20110726
AP	- US201213559431 20120726
DT	- **



- CT
- || R141 (A1)
[US7344699](#) B2 20080318 [
] (LAPPIN TERENCE [GB], et al);
[WO2009012109](#) A2
20090122 [] (UNIV EMORY
[US], et al)
 - || STSE (B2)
[US7344699](#) B2 20080318 [
] (LAPPIN TERENCE [GB], et al);
[WO2009012109](#) A2
20090122 [] (UNIV EMORY
[US], et al)
- CTNP
- || R141 (A1)
[] - Yang et al. Clin Cancer
Res 16(10) p 2833-2844, May
152010
[] - Gao et al. Nature
Biotechnology 22(6), p 969 -
9762004
[] - Samia et al. JACS 125
(51)p 15736 - 157372003
[] - Kukowska-Latallo et al.
Cancer Res 65(12) p 5317-
53242005
 - || STSE (B2)
[] - Yang et al. Clin Cancer
Res 16(10) p. 2833-2844, May
15, 2010.
[] - Gao et al. Nature
Biotechnology 22(6), p. 969-
976, 2004.
[] - Samia et al. JACS 125
(51)p. 15736-15737, 2003.
[] - Kukowska-Latallo et al.
Cancer Res 65(12) p. 5317-
5324, 2005.
- CCI
- [A61K31/137](#) ; [A61K31/352](#) ;
[A61K31/357](#) ; [A61K31/366](#) ;
[A61K31/381](#) ; [A61K31/405](#) ;
[A61K31/5375](#) ; [A61K31/713](#) ;
[A61K47/545](#) ; [A61K47/55](#) ;
[A61K47/6929](#) ;
[A61K49/0032](#) ; [A61P13/08](#) ;
[C12N15/1137](#) ;
[C12Y104/03004](#)
- CCA
- [C12N2310/14](#) ;
[C12N2310/531](#)
- CI
- A61K31/137 (EP, US)
 - A61K31/352 (EP, US)
 - A61K31/357 (EP, US)
 - A61K31/366 (EP, US)
 - A61K31/381 (EP, US)

	- A61K31/405 (EP, US) - A61K31/5375 (EP, US) - A61K31/713 (EP, US) - A61K47/545 (EP, US) - A61K47/55 (EP) - A61K47/6929 (EP) - A61K49/0032 (EP, US) - A61P13/08 (EP) - C12N15/1137 (EP, US) - C12Y104/03004 (EP, US)
CA	- C12N2310/14 (EP, US) - C12N2310/531 (EP, US)
PA	- (A1) UNIV SOUTHERN CALIFORNIA [US]; SHIH JEAN C [US]; CHUNG LELAND [US]; ZHAU HAIYEN E [US]; WU BOYANG JASON [US]; OLENYUK BOGDAN Z [US] - (B2) SHIH JEAN C [US]; CHUNG LELAND [US]; ZHAU HAIYEN E [US]; WU BOYANG JASON [US]; OLENYUK BOGDAN Z [US]; UNIV SOUTHERN CALIFORNIA [US]
TI	- (A1) MONOAMINE OXIDASE INHIBITORS AND METHODS FOR TREATMENT AND DIAGNOSIS OF PROSTATE CANCER - (B2) Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer
AB	- (A1 B2) A mechanism of monoamine oxidases (MAOs) driven epithelium-to-mesenchymal transition (EMT) is disclosed. Also disclosed are methods for treating cancer by inhibiting or suppressing MAOs in cancer cells. Novel MAOs inhibitors, such as small molecules, siRNA, shRNA, antisense oligonucleotides, aptamers, decoys, and pharmaceutical compositions useful for

treating **cancer** by disrupting the workings of MAOs are provided. In particular, a class of conjugates formed by covalently conjugating near infrared dye 783, IR-780, and MHI-148 to a MAO inhibitor, such as clorgyline, with and without encapsulation in a nanoparticle is provided. Other aspects of the invention include methods for forming the nano-conjugates, method for **monitoring** treatment progress in a **cancer** patient by **monitoring** the changes in MAO activity, methods for screening patients who are at risk of **cancer** or differentiating different forms of **cancer** by assaying the level and location of MAO activity.

45/187 © EPODOC / EPO

PN - [WO2013065019](#) A1 20130510
 PR - EP20110306438 20111104
 AP - WO2012IB56116 20121102
 DT - **
 CT - |EP| ISR (A1)
[XP055021681](#) A[AD];
[XP055021802](#) A[A];
[XP025298554](#) A[A];
[WO02098358](#) A2 20021212
 [X] (EOS BIOTECHNOLOGY INC [US])
 [X] 1,3,4,6,7
 * page 92, line 1 - line 27 *
 * page 93, line 5 - line 13 *
 * page 107, line 39 *
 * claims 1-12 *
 * page 54, line 28 - line 30 *
 * page 58, line 9 - line 16 *
 * page 60, line 1 - line 23 *
 * page 71, line 7 - line 9 *;
[XP001537431](#) A[A];
[US2010098702](#) A1 20100422
 [A] (WANG LONGGUI [US], et al)
 [A] 8
 * claims 1-16 *;
[WO2005027833](#) A2



20050331 [A] (AVI
 BIOPHARMA INC [US], et al)
 [A] 8
 * claims 1-11 *;
[WO02066492](#) A2 20020829
 [A] (SANOFI SYNTHELABO [FR],
 et al)
 [A] 8
 * claims 1,6,7,11,12,14,16 *;
[WO2012029023](#) A1
 20120308 [AP] (UNIV
 PROVENCE AIX MARSEILLE 1
 [FR], et al)
 [AP] 8
 * claims 1-20 *
 * page 12, line 5 - line 10;
 figures 1-9 *
 * page 12, line 18 - line 20 *
 * page 8, line 33 - page 9,
 line 30 *

CTNP

- |EP| ISR (A1)
 [AD] - C BERENGUER ET AL,
 "Adrenomedullin, an
 autocrine/paracrine factor
 induced by androgen
 withdrawal, stimulates
 'neuroendocrine phenotype'
 in LNCaP prostate tumor
 cells", ONCOGENE,
 (20080117), vol. 27, no. 4, doi:
[10.1038/sj.onc.1210656](#), ISSN
 0950-9232, pages 506 - 518,
 XP055021681
 [AD] 1
 * abstract *
 * Relevant for non unity *
 [A] - ROCCHI ET AL,
 "Expression of
 adrenomedullin and peptide
 amidation activity in human
 prostate cancer and in human
 prostate cancer cell lines.",
 CANCERRESEARCH,
 (20010201), vol. 61, no. 3,
 ISSN 0008-5472, pages 1196 -
 1206, XP055021802
 [A] 1
 * abstract *
 * relevant for non unity *
 [A] - FINA F ET AL,
 "Molecular profile of
 androgen-independent
 prostate cancer xenograft

LuCaP 23.1", JOURNAL OF
 STEROID BIOCHEMISTRY AND
 MOLECULAR BIOLOGY,
 ELSEVIERSCIENCE LTD.,
 OXFORD, GB, vol. 96, no. 5,
 doi:[10.1016/J.JSBMB.
 2005.04.041](https://doi.org/10.1016/J.JSBMB.2005.04.041), ISSN 0960-0760,
 (20050901), pages 355 - 365,
 (20050901), XP025298554

[A] 1

* abstract *

* relevant for non unity *

[A] - ROCCHI PALMA ET AL,
 "Molecular profile integrating
 different pathways
 associated with the androgen-
 independent progression in
 LuCaP 23.1 xenograft.",
 PROCEEDINGS OF THE
 AMERICAN ASSOCIATION FOR
 CANCERRESEARCHANNUAL
 MEETING, & 94TH ANNUAL
 MEETING OF THE AMERICAN
 ASSOCIATION FOR CANCER
 RESEARCH; WASHINGTON, DC,
 USA; JULY 11-14, 2003,
 (200307), vol. 44, ISSN 0197-
 016X, page 939, XP001537431

[A] 1-7

* abstract *

- | | |
|-----|---|
| CCI | - A61P35/00 ; A61P43/00 ;
C07K16/22 ; C07K16/2863 ;
C07K16/3069 ;
G01N33/57434 |
| CCA | - C07K2317/73 ;
G01N2333/575 |
| CI | - A61P35/00 (EP)
- A61P43/00 (EP)
- C07K16/22 (EP)
- C07K16/2863 (EP)
- C07K16/2869 (US)
- C07K16/3069 (EP)
- G01N33/54306 (US)
- G01N33/57434 (EP) |
| CA | - C07K2317/73 (EP)
- G01N2333/575 (EP) |
| PA | - UNIV AIX MARSEILLE [FR] |
| TI | - DIAGNOSTICANDTREATMENT
OF AN ANDROGEN-
INDEPENDENT PROSTATE
 CANCER |

AB - The present invention relates to a method for **monitoring** the tumor growth of an androgen-independent **prostate cancer** in a subject, by determining the amount of at least one adrenomedullin receptor and optionally adrenomedullin in a **prostate cancer** cell obtained from said subject. The present invention also relates to a pharmaceutical composition comprising an anti-adrenomedullin antagonist antibody and/or at least one anti-adrenomedullin receptor antagonist antibody for treating an androgen-independent **prostate cancer**.

46/187 © EPODOC / EPO

PN - [WO2012071096](#) A2 20120531

PNFP - WO2012071096 A3 20120816

PR - US20100379875P 20100903

AP - WO2011US50487 20110906

DT - *; Rep

CTNP - |KR| ISR (A3)
 [X] - HUNG, J. ET AL.,
 "Genomic and functional evidence for an ARID1A tumor suppressor role", GENES, CHROMOSOMES & CANCER, (20070510), vol. 46, pages 745 - 750
 [X] - CALIN, G. A. ET AL., "Low frequency of alterations of the a(PPP2R1A) and b (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms", ONCOGENE, (20000224), vol. 19, pages 1191 - 1195
 [XP] - JONES, S. ET AL., "Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma", SCIENCE, (20101008), vol. 330, no. 6001, pages 228 - 231

	[XP] - MAEDA, D. ET AL., "Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCE, (20101213), vol. 11, pages 5120 - 5128 [XP] - MCCONECHY, M. K. ET AL., "Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas", JOURNAL OF PATHOLOGY, (201104), vol. 223, pages 567 - 573 [X] - WIEGAND, K. C. ET AL., "ARID1A mutations in endometriosis associated ovarian carcinomas", NEW ENGLAND JOURNAL OF MEDICINE, (20101014), vol. 363, no. 16, pages 1532 - 1543
CCI	- A61K31/7088 ; A61K31/711 ; C12Q1/6886 ; G01N33/5011
CCA	- C12Q2600/156
CI	- A61K31/7088 (EP, US) - A61K31/711 (EP, US) - C12Q1/6886 (EP, US) - G01N33/5011 (EP, US)
CA	- C12Q2600/156 (EP, US)
PA	- (A2 A3) UNIV JOHNS HOPKINS [US]; VOGELSTEIN BERT [US]; KINZLER KENNETH W [US]; VELCULESCU VICTOR [US]; PAPADOPOULOS NICKOLAS [US]; JONES SIAN [US]
TI	- (A2 A3) ARID1A AND PPP2R1A MUTATIONS IN CANCER
AB	- (A2 A3) Two genes, ARID1A (AT-rich interactive domain- containing protein 1A) and PPP2R1A (protein- phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer , diagnosing cancer ,

contributing to a diagnosis of **cancer**, confirming a diagnosis of **cancer**, identifying appropriate treatments for **cancer**, **monitoring** treatment of **cancer**, and evaluating treatment protocols for **cancer**, including ovarian clear cell carcinoma, breast **cancer**, colon **cancer**, gastric **cancer**, lung **cancer**, medulloblastoma, pancreatic **cancer**, and **prostate cancer**.

47/187 © EPODOC / EPO

PN - [US2012129788](#) A1 20120524

PNFP - US8778621 B2 20140715

PR - EP20090159960
20090512; EP20090169739
20090908; WO20101B52072
20100511

AP - US201013320050 20100511

DT - **

CT - || R141 (A1)
[US2005095634](#) A1 20050505
[] (BAKER JOFFRE B [US], et al);
[US2011136115](#) A1 20110609
[] (SLEDZIEWSKI ANDREW Z [US], et al)
- || STSE (B2)
[US2005095634](#) A1 20050505
[] (BAKER JOFFRE B [US], et al);
[US2011136115](#) A1 20110609
[] (SLEDZIEWSKI ANDREW Z [US], et al)

CTNP - || R141 (A1)
[] - Tockman et al, Cancer Res., 199252:2711s-2718s
[] - Slamon et al, Science Vol. 235, January 1987pages 177-182
[] - Rahrmann et al, Cancer Res, epub April 28, 200969: 4388-4397
[] - Mikolajczyk et alClin. Biochem. (2004) 37 p519-528
- || STSE (B2)
[] - Tockman et al, Cancer Res., 199252:2711s-2718s.



[] - Slamon et al, Science
vol. 235, Jan. 1987pp. 177-
182.
[] - Rahrmann et al, Cancer
Res, epub Apr. 28, 200969:
4388-4397.
[] - Mikolajczyk et alClin.
Biochem. (2004) 37 p. 519-
528.

CCI - [A61P13/08](#) ; [A61P35/00](#) ;
[A61P43/00](#) ; [C12N9/16](#) ;
[C12N15/1137](#) ; [C12N15/115](#) ;
[C12Q1/44](#) ; [C12Q1/6886](#) ;
[C12Y301/04017](#) ;
[G01N33/57434](#)

CCA - [C12N2310/11](#) ;
[C12N2310/14](#) ;
[C12N2310/16](#) ;
[C12Q2600/106](#) ;
[C12Q2600/112](#) ;
[C12Q2600/158](#) ;
[G01N2800/52](#)

CI - A61P13/08 (EP)
- A61P35/00 (EP)
- A61P43/00 (EP)
- C12N9/16 (EP, KR)
- C12N15/1137 (EP, KR)
- C12N15/115 (EP, KR)
- C12Q1/44 (EP)
- C12Q1/6886 (EP, KR)
- C12Y301/04017 (EP)
- G01N33/57434 (EP, KR)
- G01N33/6893 (KR)

CA - C12N2310/11 (EP)
- C12N2310/14 (EP)
- C12N2310/16 (EP)
- C12Q2600/106 (EP, KR)
- C12Q2600/112 (EP)
- C12Q2600/118 (KR)
- C12Q2600/158 (EP, KR)
- G01N2800/342 (KR)
- G01N2800/52 (EP, KR)

PA - (A1)
HOFFMANN RALF [DE];
HOUGLAS MILES DOUGLAS
[GB]; HENDERSON DAVID
JAMES PETER [GB]; UNIV
GLASGOW [GB]; KONINKL
PHILIPS ELECTRONICS NV [NL]
- (B2)

HOFFMANN RALF [DE];
HOUSLAY MILES DOUGLAS
[GB]; HENDERSON DAVID
JAMES PETER [GB]; KONINKL
PHILIPS NV [NL]

TI

- (A1)
PHOSPHODIESTERASE 4D7 AS
MARKER FOR MALIGNANT,
HORMONE-
SENSITIVE **PROSTATE CANCER**
- (B2)
Phosphodiesterase 4D7 as
marker for malignant,
hormone-sensitive **prostate
cancer**

AB

- (A1 B2)
The present invention relates
to phosphodiesterase 4D7
(PDE4D7) for use as a marker
for malignant, hormone-
sensitive **prostate cancer**,
wherein the expression of the
marker is increased when
comparing the expression in
malignant, hormone-
sensitive **prostate cancer**
tissue, to the expression in
normal tissue or
benign **prostate** tumor tissue,
and the use of PDE4D7 as a
diagnostic marker for
malignant, hormone-
sensitive **prostate cancer**. The
present invention also relates
to a composition for
diagnosing,
detecting, **monitoring** or
prognosticating malignant,
hormone-sensitive **prostate
cancer**, a corresponding
detection method, a method
allowing to discriminate
between a benign and
malignant hormone-
sensitive **prostate cancer** and
a method of data acquisition,
as well as corresponding
immunoassays. The present
invention also relates to a
method of identifying an
individual for eligibility for
malignant, hormone-
sensitive **prostate cancer** as

well as an immunoassay for stratifying an individual with such **prostate cancer**. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive **prostate cancer**.

48/187 © EPODOC / EPO

PN - [US2012082618](#) A1 20120405

PNFP - US8512702 B2 20130820

PR - US201113325126
20111214; US20100879641
20100910; US20040543572
20040128; WO2004CA00127
20040128; US20030442897P
20030128

AP - US201113325126 20111214

DT - **

CCI - [A61K38/2013](#) ; [A61K38/212](#) ;
[A61K39/0011](#) ; [A61K47/643](#) ;
[A61K47/646](#) ; [A61K47/6869](#) ;
[A61K51/1072](#) ; [A61P35/00](#) ;
[C07K14/705](#) ; [C07K16/3069](#) ;
[C07K16/3076](#) ;
[G01N33/57419](#)

CCA - [A61K2039/505](#) ;
[A61K2039/6081](#) ;
[C07K2317/34](#) ; [G01N2800/52](#)

CLC - [A61K38/2013](#) ,
[A61K2300/00](#) , INV
- [A61K38/212](#) , [A61K2300/00](#) ,
INV

CI - A61K38/2013 (EP, US)
- A61K38/212 (EP, US)
- A61K39/0011 (EP, US)
- A61K39/001195 (US)
- A61K47/643 (EP, US)
- A61K47/646 (EP, US)
- A61K47/6869 (EP, US)
- A61K51/1072 (EP, US)
- A61P35/00 (EP)
- C07K14/705 (EP, US)
- C07K16/3069 (EP, US)
- C07K16/3076 (EP, US)
- G01N33/57419 (EP, US)


CA - A61K2039/505 (EP, US)



- A61K2039/6081 (EP, US)
- C07K2317/34 (EP, US)
- G01N2800/52 (EP, US)
- CL - A61K38/2013, A61K2300/00, INV (EP, US)
- A61K38/212, A61K2300/00, INV (EP, US)
- PA - (A1 B2)
CUELLO CLAUDIO [CA];
SARAGOV URI [CA]; DU
RUISSEAU PIERRE [CA]; GOLD
PHIL [CA]; BERNARD NICOLE
[CA]; MOFFETT SERGE [CA];
PROSCAN RX PHARMA INC [CA]
- TI - (A1)
PROSTATE CANCER DIAGNOSIS
AND TREATMENT
- (B2)
Prostate cancer diagnosis and
treatment
- AB - (A1 B2)
The present invention relates
to novel antibodies and their
use for detecting, imaging,
staging, treating
and **monitoring of prostate
cancer**, and/or metastasis
thereof. The present invention
also relates to novel
pharmaceutical compositions
for the treatment of **prostate
cancer**. Furthermore the
present invention relates to
assay systems and kits for
detecting, imaging, staging,
treating and **monitoring
of prostate cancer**, and/or
metastasis thereof.

49/187 © EPODOC / EPO

- PN - [US2012065148](#) A1 20120315
- PNFP - US8753892 B2 20140617
- PR - EP20090159960
20090512; WO20101B52073
20100511
- AP - US201013320283 20100511
- DT - **
- CT - || R141 (A1)
[WO03044170](#) A2 20030530 [
(MEMORY PHARM CORP



[US], et al);
[US2005132428](#) A1 20050616
 [] (WANG DAGUANG [US], et al);
[US2012129788](#) A1 20120524
 [] (HOFFMANN RALF [DE], et al)
 - || STSE (B2)
[US2005132428](#) A1 20050616
 [] (WANG DAGUANG [US], et al);
[US2012129788](#) A1 20120524
 [] (HOFFMANN RALF [DE], et al);
[WO03044170](#) A2 20030530 [] (MEMORY PHARM CORP [US], et al)
 CTNP - || R141 (A1)
 [] - DhedaKeertan et al; "Validation of housekeeping genes for normalizing RNA expression in real time PCR." BioTechniques (2004) 37 p112-119
 [] - MorenoJose G. et al; "Detection of hematogenous micrometastasis in patients with prostate cancer." Cancer. Res. (1992) 52 p6110-6112
 [] - WangDaguang et al; "Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7." Cell. Signal. (2003) 15(9) p883-891
 [] - GrossmannMichael E. et al; "Androgen receptor signaling in androgen refractory prostate cancer." J. Nat. Canc. Inst. (2001) 93(22) p1687-1697
 [] - AusG. et al; "EAU guidelines on prostate cancer." European Urology (2005) 48 p546-551
 [] - DasAnindita et al; "Phosphodiesterase-5 inhibitor sildinafil preconditions adult cardiac myocytes against necrosis and apoptosis." J. Biol. Chem. (2006) 280(13) p12944-12955
 [] - MikolajczykStephen D. et al; "Are multiple markers

the future of prostate cancer diagnostics?" Clin. Biochem. (2004) 37 p519-528

- || STSE (B2)
 - [] - DhedaKeertan et al; "Validation of housekeeping genes for normalizing RNA expression in real time PCR." BioTechniques (2004) 37 p. 112-119.
 - [] - MorenoJose G. et al; "Detection of hematogenous micrometastasis in patients with prostate cancer." Cancer. Res. (1992) 52 p. 6110-6112).
 - [] - WangDaguang et al; "Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7." Cell. Signal. (2003) 15(9) p. 883-891.
 - [] - GrossmannMichael E. et al; "Androgen receptor signaling in androgen refractory prostate cancer." J. Nat. Canc. Inst. (2001) 93(22) p. 1687-1697.
 - [] - AusG. et al; "EAU guidelines on prostate cancer." European Urology (2005) 48 p. 546-551.
 - [] - DasAnindita et al; "Phosphodiesterase-5 inhibitor sildinafil preconditions adult cardiac myocytes against necrosis and apoptosis." J. Biol. Chem. (2006) 280(13) p. 12944-12955.
 - [] - MikolajczykStephen D. et al; "Are multiple markers the future of prostate cancer diagnostics?" Clin. Biochem. (2004) 37 p. 519-528.

- CCI - [A61P13/08](#) ; [C12N9/16](#) ; [C12N15/1137](#) ; [C12N15/115](#) ; [C12Q1/44](#) ; [C12Q1/6886](#) ; [C12Y301/04017](#) ; [G01N33/57434](#)
- CCA - [C12N2310/113](#) ; [C12N2310/14](#) ; [C12N2310/141](#) ; [C12N2310/16](#) ;

[C12Q2600/106](#) ;
[C12Q2600/112](#) ;
[G01N2800/52](#) ; [Y10S436/813](#)

- CI
- A61P13/08 (EP)
 - C12N9/16 (EP, CN, KR)
 - C12N15/1137 (EP, CN, KR)
 - C12N15/115 (EP, CN, KR)
 - C12Q1/44 (EP, CN)
 - C12Q1/6886 (EP, CN, KR, RU)
 - C12Y301/04017 (EP, CN)
 - G01N33/57434 (EP, CN, KR)
 - G01N33/68 (US)
 - G01N33/6893 (KR)
- CA
- C12N2310/113 (EP, CN)
 - C12N2310/14 (EP, CN)
 - C12N2310/141 (EP, CN)
 - C12N2310/16 (EP, CN)
 - C12Q2600/106 (EP, CN, KR)
 - C12Q2600/112 (EP, CN, KR)
 - C12Q2600/118 (KR)
 - G01N2333/916 (CN, US)
 - G01N2800/52 (EP, KR)
 - G01N2800/54 (KR, US)
 - Y10S436/813 (EP, US)
- PA
- (A1)
HOFFMANN RALF [DE];
HOUSLAY MILES DOUGLAS
[GB]; HENDERSON DAVID
JAMES PETER [GB]; UNIV
GLASGOW [GB]; KONINKL
PHILIPS ELECTRONICS NV [NL]
 - (B2)
HOFFMANN RALF [DE];
HOUSLAY MILES DOUGLAS
[GB]; HENDERSON DAVID
JAMES PETER [GB]; KONINKL
PHILIPS NV [NL]
- TI
- (A1)
PHOSPHODIESTERASE 4D7
AS **PROSTATE CANCER** MARKER
 - (B2)
Phosphodiesterase 4D7
as **prostate cancer** marker
- AB
- (A1 B2)
The present invention relates
to phosphodiesterase 4D7
(PDE4D7) for use as a marker
for **prostate cancer**, and the
use of PDE4D7 as a marker
for diagnosing,

detecting, **monitoring** or
 prognosticating **prostate**
cancer or the progression
 of **prostate cancer**. The
 present invention also relates
 to a composition for
 diagnosing,
 detecting, **monitoring** or
 prognosticating **prostate**
cancer or the progression
 of **prostate cancer**, a
 corresponding method and
 immunoassay, a method for
 diagnosing, **monitoring** or
 prognosticating hormone-
 resistant **prostate cancer** vs.
 hormone-sensitive **prostate**
cancer, a corresponding
 immunoassay, a method of
 data acquisition, an
 immunoassay for diagnosing,
 detecting, **monitoring** or
 prognosticating **prostate**
cancer or the progression
 of **prostate cancer**, a method
 of identifying an individual
 for eligibility for **prostate**
cancer therapy, an
 immunoassay for stratifying
 an individual or cohort of
 individuals with a **prostate**
cancer disease, an
 immunoassay for stratifying
 an individual with **prostate**
cancer, as well as a
 pharmaceutical composition
 comprising a compound
 directly stimulating or
 modulating the activity of
 PDE4D7, a compound
 indirectly stimulating or
 modulating the activity of
 PDE4D7, the PDE4D7 protein
 or a biologically active
 equivalent thereof, a nucleic
 acid encoding and expressing
 PDE4D7, a miRNA inhibitor
 specific for PDE4D7 miRNAs,
 a demethylation agent and/or
 a phosphodiesterase
 displacement factor.

PN	- US2012058131 A1 20120308	
PR	- WO2010IB00102 20100121; US201013145770 20100121; US20090146172P 20090121	
AP	- US201013145770 20100121	
DT	- **	
CT	- R141 (A1) WO2006110593 A2 00000000 []	
CCI	- A61K47/6849 ; A61K47/6857 ; A61K47/6859 ; A61K47/6861 ; A61K47/6863 ; C07K16/28 ; C07K16/3023 ; C07K16/303 ; C07K16/3038 ; C07K16/3046 ; G01N33/57407 ; G01N33/57419 ; G01N33/57423 ; G01N33/57434 ; G01N33/57438	
CI	- A61K47/6849 (EP) - A61K47/6857 (EP) - A61K47/6859 (EP) - A61K47/6861 (EP) - A61K47/6863 (EP) - C07K16/28 (EP) - C07K16/3023 (EP) - C07K16/303 (EP) - C07K16/3038 (EP) - C07K16/3046 (EP) - G01N33/57407 (EP) - G01N33/57419 (EP) - G01N33/57423 (EP) - G01N33/57434 (EP) - G01N33/57438 (EP)	
PA	- ROHLFF CHRISTIAN [GB]; OXFORD BIOTHERAPEUTICS LTD [GB]	
TI	- PTA089 PROTEIN	
AB	- The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer , colorectal cancer , head and neck cancer , kidney cancer ,	

liver **cancer**, lung **cancer**,
prostate cancer or
skin **cancer**, for **monitoring**
the effectiveness of
bladder **cancer**,
colorectal **cancer**, head and
neck **cancer**, kidney **cancer**,
liver **cancer**, lung **cancer**,
prostate cancer or skin **cancer**
treatment, and for drug
development.

[SS 71]